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Congenital heart disease occurs in 0.8-1% of children. A proportion of these patients will 
require interventional treatment in the form of cardiac catheterisation or surgery, whilst some 
will only require medical therapy. Echocardiography is the investigation of choice for 
diagnosis and follow-up of these patients, whilst magnetic resonance imaging (MRI) is now 
increasingly used in most centres to assess complex congenital cases and to answer specific 
questions, not possible to address with echocardiography. The ability to obtain anatomical 
together with quantitative physiological information, such as cardiac function and flows in 
one examination has led to more detailed assessment and analysis of congenital heart defects 
and continues to improve our understanding about congenital heart disease and its treatment 
options.  
Cardiac MRI scans have now mostly replaced cardiac catheterisation procedures, 
routinely performed up to a few years ago to aid diagnosis. In parallel, a new form of hybrid 
catheterisation has emerged by combining MRI with simultaneous pressure measurement in 
different cardiac chambers and vascular structures. The combination of X-Ray and MRI 
guided (XMR) catheterisations can address clinical questions, such as estimation of 
pulmonary vascular resistance and cardiac output response to stress accurately, without the 
limitation of haemodynamic assumptions during calculations.
 
Further to more accurate 
physiological information, XMR catheterisation can also offer detailed anatomical 
information of structures not well seen on echocardiography or MRI alone, and most 
importantly limit or eliminate the radiation exposure to patient that have been repetitively 
exposed to X-Ray radiation. 
The purpose of the research work presented was two-fold: a. to extend the potentials of 
XMR-guided cardiac catheterisations, particularly in the area of pre-operative and post-
interventional evaluation of congenital heart disease and b. to advance our already established 
programme of solely MR-guided diagnostic cardiac catheterisations in order to materialise the 
first-in-man solely MR-guided therapeutic cardiac catheterisations. In this way, transcatheter 
interventional procedures were aimed to be performed in the MR scanner in a similar fashion 
and with similar equipment to the ones used in the traditional catheterisation suite, without the 
exposure to ionising radiation. The work towards materialisation of this idea and the world-
first clinical trial on solely MRI-guided cardiac interventions for congenital heart disease are 
being presented in this thesis. 
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Congenital heart disease occurs in 0.8-1% of children. A proportion of these patients will 
require interventional treatment in the form of cardiac catheterisation or surgery, whilst some 
will only require medical therapy. Echocardiography is the investigation of choice for 
diagnosis and follow-up of these patients, whilst magnetic resonance imaging (MRI) is now 
increasingly used in most centres to assess complex congenital cases and to answer specific 
questions, not possible to address with echocardiography. Diagnostic cardiac catheterisation is 
another important tool performed prior to planning palliative or corrective surgical procedures. 
During a cardiac catheterisation procedure, the cardiac anatomy is defined with the aid of 
ventriculograms and angiograms performed with contrast agents and under X-Ray 
fluoroscopic guidance. In addition, haemodynamic assessement as well as assessment of the 
physiology (shunts, Qp:Qs etc) can be performed. 
In most recent years cardiac MRI scans have replaced diagnostic cardiac catheterisation 
procedures to a significant degree, by providing the anatomic as well as the above mentioned 
physiological details with great accuracy. To this end, cardiac catheterisations nowadays are 
mostly reserved for cases where haemodynamic assessment is essential or when the 
performance of a percutaneous intervention is anticipated. In parallel, a new form of hybrid 
catheterisation has emerged by combining MRI with simultaneous pressure measurement in 
various cardiac chambers and vascular structures. Paired X-Ray and MRI guided (XMR) 
catheterisations can address clinical questions, such as estimation of pulmonary vascular 
resistance and cardiac output response to stress accurately, without the limitation of 
haemodynamic assumptions made during calculations.
 
Further to more accurate physiological 
information, XMR catheterisation can also offer detailed anatomical information of structures 
not well seen on echocardiography or MRI alone, such as small aortopulmonary collateral 
arteries, so that fluoroscopy and MRI can be combined in one procedure to avoid two general 
anaesthetic sessions in the same child and for the same purpose. Most importantly, hybrid 
XMR guided catheterisations can reduce significantly the patient radiation exposure. This is 
very important in this particular patient population due to the specific risks and concerns 
 17 
raised with regards to the cummulative exposure risk to patients who need repetitive 
assessments and treatments involving ionising radiation.  
To this end, beyond the replacement of diagnostic cardiac catheterisations by more 
sophisticated echocardiographic studies and magnetic resonance scans, back in 2002 our 
group pioneered the first-in-man sole MRI guided diagnostic cardiac catheterisation 
procedures for patients where haemodynamic assessment of their congenital cardiac defect 
was essential. A further goal since has been a. to extend the potentials of XMR-guided cardiac 
catheterisations, particularly in the area of pre- and post-operative and interventional 
evaluation of congenital heart disease and address physiological questions (such as response 
of cardiac output and haemodynamic measurements during pharmacological stress) b. to 
advance our already established programme of solely MR-guided diagnostic cardiac 
catheterisations in order to materialise the first-in-man solely MR-guided therapeutic cardiac 
catheterisations. In this way, transcatheter interventional procedures were aimed to be 
performed in the MR scanner in a similar fashion and with similar equipment to the ones used 





The XMR interventional suite at the Evelina Children’s Hospital was used to continue with an 
advanced XMR catheterisation programme and also perform MRI-guided cardiac 
catheterisations. The XMR suite was equipped with all the necessary monitors and essential 
equipment and was configured like a conventional cardiac catheterisation laboratory. In 
particular, the suite was equipped with an angiographic pump and the invasive pressure 
monitoring was connected to the in-room consoles placed directly in front of the MRI scanner. 
Multiple projectors were set up to display real-time magnetic resonance imaging, scanner 
control and the same haemodynamic recording system as in the traditional catheterisation 
laboratory (Figures 1-1 and 1-2). By configuring the XMR laboratory like a traditional cardiac 
catheterisation laboratory, cardiac catheterisations could be undertaken in the MRI-suite with 
safety, whilst X-Ray back-up was present in case of an urgent need to switch to the X-Ray 
modality.  
In parallel, in vivo testing of a new MRI-compatible and safe guidewire manufactured 
in Germany took place in 2 animals (swine). The initial remarks and problems identified, 
mainly with its hydrophilic coating, led to the in vitro improvement of the guidewire and a 
 18 
further trial to perform solely MR-guided interventions using this guidewire in 4 more swine 
was performed. The new pre-clinical in vivo testing proved the guidewire to be succesful in 
aiding sole MRI-guided interventions, such as ballooning the pulmonary artery branches, the 
aorta and the aortic and pulmonary valves. Following the successful pre-clinical animal study, 
approval was obtained by a specialist device Ethics commitee and the UK Medicines and 
Healthcare Regulatory Authority to commence the first-in-man clinical trial of MRI-guided 
percutaneous interventions for congenital heart disease. 
The work towards materialisation of this idea and the world-first clinical trial on solely 





The first-in-man sole MRI-guided interventional programme was commenced with the 
performance of 7 MRI-guided interventions in both children and adults with congenital heart 
disease. In particular, seven patients aged 3 - 64 years were included in the trial. Five patients 
underwent successful interventions for pulmonary valve stenosis (n=4) and native aortic 
coarctation (n=1). One patient with left pulmonary artery stent underwent right heart 
catheterisation with the aid of the new MR-wire, but due to low gradient across the stent no 
intervention was required. The last patient (8 year old child) with severe aortic stenosis had an 
unsuccessful attempt at ballooning the aortic valve, due to the inability of turning the wedge 
catheter into the ascending aorta, as the balloon of the catheter kept being pushed back by the 
aortic stenosis jet. This patient was then referred for X-Ray guided balloon dilation of the 
aortic valve. 
Catheter manipulations were monitored with real time MRI sequence with interactive 
modification of imaging plane and slice position. Temporal resolution was 11-12 frames/sec. 
Median procedure and catheterisation times were 180 and 110 min, respectively. All patients 
who underwent successful MRI-guided interventions, except for the last, were discharged 
home the day after the procedure with > 50% reduction of the stenosis gradient and no 
procedural complications.  
Beyond the world-first clinical trial on MRI-guided interventions, the XMR programme was 
advanced to include patients with complex haemodynamics or unknown cardiac output 
response to stress, such as in the case of pre-liver transplantation children. By equiping the 
XMR suite with an angiographic pump and all the necessary equipment found in a traditional 
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cardiac catheterisation lab, patients requiring anatomical assessment for complex anatomy 
(such as Fallot with pulmonary atresia and major aortopulmonary collateral arteries), not well 
imaged with echocardiography or MRI, became possible to evaluate by combining an MRI 
study and a diagnostic cardiac catheterisation / angiogram in one procedure. In addition, sole 
MRI-guided diagnostic cardiac catheterisations were advanced further to include the potential 





Interventional MRI has been used in the past decade with the main aim to improve image 
guidance and limit the radiation exposure to patients and medics alike. It it thought that the 
beneficial effects of limiting the radiation exposure will be particularly important in children 
and adults with congenital heart disease. These patients are subjected to several procedures 
involving radiation in their lifetime such as X-Ray radiograms, cardiac catheterisations, CT 
scans etc. Being able to limit the radiation exposure is crucial, especially in the younger and 
immature patients. To this end, after a successful MRI-guided diagnostic cardiac 
catheterisation programme, we sought to expand and successfully performed the first-in-man 
sole MRI-guided percutaneous interventions. In addition, where sole MRI guidance was not 
possible, complex hybrid XMR catheterisations were performed to aid diagnosis and 
management, whilst limiting radiation exposure to a minimum. An increasing number of 
medical centers are now using hybrid XMR catheterisations, not neccesarily performed in the 
same suite but also in adjacent labs. New MRI-compatible and safe equipment are being 
manufactured and tested and novel MRI sequences are being developed to assist in the 
performance of real-time interventional MRI. Although interventional MRI is still a research 
tool, it is envisaged that with the current advances taking place, sole MRI-guided 
interventions will become more routine in the future, at least for patients where precise 2D 




Figure 1-1. The XMR interventional suites at the Evelina Children’s Hospital, St Thomas’ Campus (top) and 




Figure 1-2.  
The in-room monitors display real-time MRI images and haemodynamic pressure traces during 
the MR-guided intervention. They can be moved across both the bottom end and the top end of 




CHAPTER 2. INTRODUCTION 
 
 
2.1. Description and Epidemiology of Congenital heart disease 
 
Congenital heart disease is the commonest single group of congenital anomalies, accounting 
for about 30% of their total. Malformations of the heart occur during embryogenesis and they 
result from developmental errors during cardiac development. The cardiac malformations 
follow specific patterns, just as other malformations do, and these patterns present variability 
in their gradation. There are 8 common congenital heart disease lesions that account for about 
80% of all cases (ventricular and atrial septal defect, patent ductus arteriosus, tetralogy of 
Fallot, pulmonary stenosis, coarctation of the aorta, aortic stenosis and transposition of the 
great arteries). The remaining 20% of congenital heart lesions represent more rare and 
complex lesions.  
The collective incidence of congenital heart disease is 0.8% of live births. In 0.4% of live 
births the disease is moderate  and may not need treatment, whilst in the other 0.4% the disease 
may need medical, transcatheter or surgical treatment. With the advancement of the 
therapeutic options available, approximately 85% of infants born with congenital heart disease 
in developed countries reach adulthood.  
 
 
 2.2. Increased survival and complications 
 
The first congenital cardiac operation performed was in 1938 by Robert Gross who ligated a 
patent ductus arteriosus in a 7 year old child. A few years later, in 1944, the end of a 
subclavian artery was anastomosed to a pulmonary artery in a patient with Tetralogy of Fallot 
to create a Blalock-Taussig shunt. Corrective heart surgery of more difficult and complex 
lesions started taking place in the 60’s and 70’s. Nowadays, the operative mortality of 
complex lesions can be as low as 1-3%. As a result, there is a growing population of patients 
that reach adulthood. It is estimated that in the United States there are more adults with 
congenital heart disease than there are infants and children and approximately 20.000 
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operations are perfomed annually in this patient population. Understanding the 
pathophysiology of their disease and the progression or alterations of their haemodynamics is 
vital in order to guide their management, medical or interventional. To this end, detailed 
assessment made by modern echocardiographic techniques, cardiac catheterisation and MRI 
are combined to provide as much data as possible for clinical and research purposes. 
Improved understanding and better management of patients with congenital heart disease 
from the onset of the disease detection is expected to lead to better long term outcomes.  
 
 
2.3.  Imaging congenital heart disease  
 
A few decades ago, a chest radiograph and thorough clinical examination used to be all that 
was available to categorise the patient’s congenital heart disease and make a broad diagnosis. 
With the emergence of echocardiography, the diagnosis of congenital heart disease became 
precise and accurate. Echocardiography provides 2-dimensional and colour Doppler 
assessment, but also 3D anatomical detail, particularly good for the atrioventricular valve 
anatomy. In addition, tissue Doppler and speckle tracking that have been more broadly 
applied recently, can help in assessing the patient’s cardiac function in more detail. 
Volumetric assessment using 3D echocardiography can be used for assessment of left 
ventricular volumes, but less well for the right ventricle, due to the proximity of the latter to 
the chest wall. 
Cardiac magnetic resonance imaging (CMR) emerged more than a decade ago and 
initially found broad acceptance in supplementing the diagnosis making, by providing 
imaging of complex lesions together with 3D imaging of the cardiac structures. Since then, 
CMR has developed to a degree that nearly every complex patient undergoes a cardiac MRI 
scan prior to a planned intervention, in order to obtain information relating to the patient’s 
physiology and exact anatomy. 
MRI is particularly useful for accurate assessment of Qp:Qs and other shunts through 
cardiac chambers, vessels or prosthetic grafts. It can identify anatomical stenosis, even of 
small vessels, eliminating the need for cardiac catheterisation and provides ventricular 
function and volumetries with great accuracy. Although these days there are set protocols for 
examining different congenital heart disease entities, most of the sequences used are the same 
and interchange within the protocols to target the anatomy in question. The most frequent 
 23 




2.4.  Imaging congenital heart disease with cardiac magnetic resonance 
imaging 
 
2.4.1. Physical principles of magnetic resonance imaging 
Magnetic resonance is a phenomenon that arises when nuclei with a characteristic spin 
quantum number that is greater than zero are placed in a magnetic field. The spin 
characteristic of the charged nucleus induces a magnetic field with a magnitude and direction 
represented by the magnetic moment ().  In the absence of an external magnetic field, the 
magnetic moments in a collection of nuclei will be randomly orientated.  However, when a 
static magnetic field is applied, these magnetic moments assume discrete orientations, either 
parallel or anti-parallel to the direction of the applied field.  In the absence of thermal 
fluctuations, nuclei will eventually obtain  parallel orientation with the imposed field because 
this is the lowest energy state.  The surfeit of nuclei that are parallel over those that are anti-
parallel is called polarisation and results in a net macroscopic nuclear magnetisation.  This is a 
small effect with a polarisation of only about 1 in 10
5
 for hydrogen nuclei in a 1 Tesla field.  
For this reason large polarising magnetic fields are required. For clinical imaging, 0.5 to 3 
Tesla field strengths are currently used. 
If the nuclear polarisation is perturbed so that it is no longer aligned with the static 
polarising field, it rotates around the direction of the imposed magnetic field.  This motion is 
called precession. The rate of precession is dependent upon the characteristics of the nuclear 
species and the strength of the field. Because the precession frequency depends on the 
magnetic field strength, and the MRI process requires the coordinated response of many 
nuclei to produce a detectable signal, the polarising field must be highly uniform. 
 RF energy is absorbed from the transmitter coil, this causes the polarisation, or net magnetic 
vector (NMV), to rotate from its equilibrium direction parallel to the static magnetic field 
through an angle which depends on the strength and duration of the RF pulse.  If a 90
o
 pulse is 
applied
,
 the NMV is rotated from the longitudinal direction to the transverse plane. The 
transverse component of the NMV induces an electromotive force (EMF) in a receive coil, 




Following the application of the RF pulse, the NMV returns to equilibrium and re-aligns 
with the main magnetic field, through a relaxation processes. Relaxation is influenced by the 
environment in which the spins exist, and is the basis of image contrast in conventional MRI.  
There are two distinct relaxation processes, which occur with exponential time courses.  T1 
recovery, or spin–lattice relaxation, depends on the energy transfer between spins and the 
surrounding lattice. T1 recovery is the process by which longitudinal magnetisation is restored 
after an RF pulse. The value of T1 in biological tissue ranges from about 50 milliseconds (ms) 
to a few seconds, depending on the kind of nuclei being stimulated, their chemical and 
physical environment, and the strength of the magnetic field. 
The second process is spin-spin relaxation, which is the process by which the transverse 
magnetisation decays as a function of time.  The time constant for transverse relaxation is 
conventionally termed T2. The transverse relaxation time of solids is very short as they have 
fixed molecules which maintain local field variations. Transverse magnetisation is maintained 
for a longer time in liquids.  In biological tissues that are visible by MRI, T2 values range 
from around 1 ms to 1 second.  In practice, the free induction decay (FID) decays away faster 
than would be predicted by T2 processes. This is because of inhomogeneities in the B0 field 
cause the local Larmor frequency to vary from location to location, which causes signal 




2.4.1.2 The spin echo 
As mentioned previously, following a RF excitation pulse, spins experiencing different 
local magnetic fields lose phase coherence causing the transverse component of magnetisation 
to decrease.  Although the signal is reduced, the T2
*
 effect causes the phases to be dispersed 
rather than randomised.  If another RF pulse is applied that flips the dispersed magnetisation 
by 180
0
, those components that are phase advanced will become phase delayed and vice versa.  
The signal during the pulse sequence changes as follows: i. Following the 90
o
 excitation pulse 
a FID is generated that decays with time constant T2* ii. The 180
o
 pulse refocuses the spins, 
and the signal is at maximum at time TE   iii. The signal decays again as the spins diphase.  
By applying a 180
o
 pulse every TE, a train of spin echoes is created.  The magnitude of the 
spin echo decays according to T2 due to time varying non-refocusable inhomogeneities. Each 
echo decays with time constant T2* due to static field inhomogeneities. 
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2.4.1.3 Image formation and spatial encoding 
In order to form an image, it is necessary to encode the received signal in such a way 
that its components can be related to the spatial position of nuclei contributing to the signal. 
The resonant frequency of a nucleus is proportional to the strength of the magnetic field.  By 
applying a magnetic field gradient which either subtracts from or adds to B0, the magnitude of 
B0 can be adjusted in a linear manner with distance. This makes the precessional frequency 
vary in a predictable linear way along the direction of the applied gradient and provides a 
basis for spatial encoding and thus image production.  
 
2.4.1.4 Frequency encoding 
Following slice selection, it is necessary to locate the signal within the slice, which 
requires spatial discrimination in two further coordinate axes. The first of these directions is 
achieved by a process called frequency encoding. Switching on the frequency encoding 
gradient causes the precessional frequency of nuclei to be altered in a linear fashion, enabling 
the location of the nuclei along the direction of the gradient to be determined according to its 
frequency.  
 
2.4.1.5 Phase encoding 
Localisation of the signal along the remaining axis of the body is described as phase 
encoding. Once again when this gradient is applied an alteration occurs in the precessional 
frequency of the nuclei along it axis, resulting in a phase shift.  When the gradient is switched 
off the magnetic field experienced by the nuclei returns to B0, but the phase difference 
between the nuclei remains.  In this way, their position along the phase encoding gradient is 
identified.  Because it is only possible to read out with one gradient active at a time (driving 
two gradients simultaneously simply results is an obliqued gradient), phase encoding is 
achieved in a stepped fashion. After each excitation a specific phase encode gradient is 
applied, then turned off before signal is recorded during the action of the frequency encode 
gradient. The phase encode gradient is then incrementally changed over a repetitive cycle of 
measurements to build up the full encoding required in that direction. The amplitude of the 
phase encoding determines the remaining dimension of the FOV.  If a succession of 180
0
 
refocusing pulses is used to create a train of multiple spin echoes, each successive echo can be 
individually phase encoded and read out with its own frequency encode gradient. This allows 
data to be acquired more rapidly and is known as a fast spin echo (FSE) approach. 
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The signals collected during the action of the frequency encode gradients for each phase 
encode gradient are digitised to form a 2 dimensional array of values that contain information 
about the distribution of signals within the excited slice. To convert this data into an image a 
frequency analysis must be performed and this is done using a two-dimensional Fourier 
transform.  The result is an MR image. 
 
2.4.2. Sequences used in imaging congenital heart disease   
 
2.4.2.1 Interactive scanning 
It is common practice in our department to perform a real-time (interactive) MRI at the 
beginning of each cardiac examination in patients with congenital heart disease. This provides 
us with a quick impression of the overall anatomy that will help us plan the subsequent 
examination. Imaging planes are defined and stored, so that they can be used later for the MRI 
sequences that will be subsequently performed. For example, storing a saggital plane of the 
aortic arch and naming it “a.arch” allows us to then use it for sequences such as black blood, 
cine spin echo loops and phase contrast flows with which we can assess the anatomy and 
define the inplane velocity across the aortic arch. 
The most commonly stored imaging planes during interactive scanning are the 
following: 
4chamber view, RVOT, LVOT, PA-TP, Ao-TP, LPA-TP, RPA-TP, SA, 3D Gadolinium 
angiogram and 3D SSFP (3D whole-heart). In addition imaging planes such as SVC, IVC, 
bicaval view etc. can be stored, depending on the requirement to study certain anatomical 
structures specific to the patient’s anatomy and physiology. 
 
2.4.2.2 Spin echo 
Spin echo sequencies use dual inversion to obtain nulling of the signal from the blood, 
hence the blood pool appears with little or no signal. As a result, the blood in the intracardiac 
cavities and the great vessel appears black, hence the name „black blood imaging“. 
In practice, fast spin echo sequencies are used nowadays to provide better nulling using 
number of signal averages of 1 or more, depending on whether the sequence is obtained 
during a breathhold or not.    
Spin echo sequencies can be weighted to T1 or T2 and thus provide information about 
tissue characterisation, such as in infiltrative cardiac muscle disease (arrhythmogenic right 
ventricular dysplasia, amyloidosis etc).  
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2.4.2.3 Gradient echo 
Gradient echo sequences result in high signal from the blood pool and therefore they are 
otherwise called „bright blood“ sequences. Gradient echo sequences were used in the past for 
angiographic MR imaging. The two dominant techniques were:  a. time of flight and b. phase 
contrast. Due to the long acquisition time, gadolinium enhanced angiography has today 
replaced angiographic MR imaging using gradient echo sequences. Instead, these sequences 
are very useful in examining the cardiac, vascular and valvar anatomy with great detail as 
well as obtaining an accurate estimation of ventricular function. For estimation of the 
anatomy, cine gradient sequences are used. With these sequencies, it is possible to acquire a 
single ECG-gated slice in dynamic fashion with a cine series of images. 20-40 different time 
frame images can be obtained for each slice in a single breath-hold, depending on the heart 
rate. Using a transverse stack of slices in the short axis plane through the ventricles, it is 
possible to estimate the ventricular ejection fraction and the ventricular volumes. In addition, 
combining the stroke volume of each ventricle with the forward flow in the great vessels 
(using the phase contrast flow sequences described below), we can derive the degree of valvar 
regurgitation at the atrioventricular valve level. 
More recently, a more modern echo technique called steady state free precession (SSFP) 
is used to obtain a 3D „whole heart“ analysis. This technique uses steady states of 
magnetisations. In general, SSFP MRI sequences are based on a low flip angle gradient-echo 
MRI sequence with a short repetition time (TR), which allows for fast imaging. In cardiac 
scanning 3D SSFP is acquired during the still period of the heart, either in end-systole or in 
end-diastole or even in both (dual phase 3D). During the cardiac still period there is no 
turbulence of flow and therefore no loss of signal, resulting in high resolution images. The 3D 
SSFP sequence can also be analysed in a way to provide 3D angiography without the use of 
contrast.  
 
2.4.2.4 Velocity and flow 
By using an adaptation to the reconstruction algorithm of phase contrast angiograms, 
velocity component information can be acquired. A subtraction technique is used, so that two 
images are obtained for each phase of the cardiac cycle. If the slice plane is perpendicular to a 
vessel (through-plane), summation of the velocities in the vessel repeated for every phase of 
the cardiac cycle can be used for estimation of blood flow in that vessel. If on the other hand, 
the slice plane is in the plane of the direction of blood flow (in-plane), then the cardiac phase 
with the highest velocity pixel can be used to provide an indication of the velocity gradient 
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across a narrowing. The peak velocity data acquired with a short enough echo time has been 
found to be accurate in comparison to Doppler echocardiography. Phase contrast through-
plane imaging across the short axis of vessels gives accurate flow information, which can be 
used to calculate intracardiac shunts and quantify the degree of valvar regurgitation.  
 
2.4.2.5 Three-dimensional contrast MR angiography 
Contrast enhanced MRA angiography has been used for over a decade now to image the 
great vessels, most commonly the aorta, pulmonary arteries and veins as well as the systemic 
veins. The timing of acquisition in relation to the contrast administration has to be adapted to 
target the structures of interest. Arterial and venous phase can be separated well, particularly 
in lower heart rates. On the contrary, in infants and young children with fast heart rates, the 
venous and arterial structures may be imaged simoultaneously. Similarly, separation of the 
venous and arterial structures will not hold in patients with intracardiac shunts, such as 
ventricular septal defects. Real time bolus detection allows more accurate timing of image 
acquisition but is also useful in recognising differential filling times between the two lungs in 
patients with unilateral severe pulmonary artery stenosis for example. 
The acquired sequence can be post-processed with tools such as maximum intensity 
projection (MIP) and multiplanar reformatting, to visualise the three-dimensional structures 
and spatial relationships between vessels. In addition, other image processing techniques, 
such as volume rendering and surface rendering allow structures of interest to be visualised in 
a three-dimensional nature. 
 
 
2.5. Aims of Thesis 
 
The feasibility of performing sole MR-guided diagnostic cardiac catheterisations under 
interactive real-time MRI was first established in our institution
 
 in 2002 
1
. In parallel, a 
facility incorporating a cardiovascular X-Ray system and a state-of-the-art scanner, called 
XMR facility, has been developed and used with specific indications. XMR catheterisations 
were initially employed and validated against standard cardiac catheterisation for the 
assessment of pulmonary vascular resistance (PVR). In the past few years the indications for 
XMR catheterisations have widened to include assessment of anatomy and function of 
univentricular hearts and haemodynamic measurement combined with cardiac output response 
to pharmacological stress. The combination of X-Ray guided cardiac catheterisation with an 
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MRI scan can result in the reduction of catheterisation time and fluoroscopy times, because 
the anatomy is obtained by the MRI scan and not by the performance of contrast angiograms. 
X-Ray fluoroscopy is therefore used only during manipulation of catheters and wires inside 
the heart. 
The purpose of the research work presented was two-fold: a. to extend the potentials of XMR-
guided cardiac catheterisations and address physiological questions (such as response of 
cardiac output and haemodynamic measurements during pharmacological stress mentioned 
above) and b. to advance our already established programme of solely MR-guided diagnostic 
cardiac catheterisations in order to materialise the first-in-man solely MR-guided therapeutic 
cardiac catheterisations. In this way, transcatheter interventional procedures were aimed to be 
performed in the MR scanner in a similar fashion and with similar equipment to the ones used 
in the traditional catheterisation suite, without the exposure to ionising radiation.  
The work towards materialisation of this idea and the world-first clinical trial on solely MRI-
guided cardiac interventions for congenital heart disease are being presented in this thesis. 
 
2.6. Overview of Thesis and chapter description 
This dissertation is submitted as a “Thesis incorporationg publication” according to the 
King’s College guidelines. 
Chapter 3 that follows is word for word our published paper on ‘MR-imaging guided 
cardiovascular interventions in young children’, published in 2012 in the “Magnetic  
Resonance Imaging Clinics of North America”.  
In addition to this publication, chapter 3.4 describes how bridging can occur between 
XMR-guided diagnostic and XMR-guided interventional procedures and 3.5 describes the 
bridging between solely MR-guided diagnostic and MR-guided interventional cardiac 
catheterisations giving word for word our publication in Heart: “Test Occlusion Of Fontan 
Fenestration:  Unique Contribution Of Interventional MRI. 
 
Chapter 4 desribes our research on cardiovascular pre-operative assessment of children 
prior to liver transplantation using: combined ‘Cardiac Catheterisation and Magnetic 
Resonance Imaging’ with Dobutamine stress. This is unpublished work on the assessment of 
cardiac output response of patients with and without fixed right heart obstructions, (such as 
valvar or branch pulmonary artery stenosis) undergoing pre-liver transplantation work-up. 
Evaluation of the XMR catheterisations performed for assessment of PVR was not one 
of the main aims of this thesis (as this work has been published by other colleagues in our 
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department previously) and therefore results of these procedures are not presented in this 
dissertation. 
 
Chapter 5 describes the preparatory research work towards the first-in-man clinical trial 
on MR-guided cardiac interventions using MR-compatible devices. Assessment of the 
catheterisation equipment and in particular the fibreglass guidewire that was planned to be 
used in the MRI environment for the performance of transcatheter interventions was 
performed in vitro. Assessment of its safety and mechanical properties are described in this 
section. 
 
Chapter 6 describes the study protocol of the first-in-man clinical trial on MR-guided 
cardiac interventions using MR-compatible devices; the background & rationale, selection 
and withdrawal of subjects, as well as the Ethics & Regulatory Approvals are presented in 
detail.  
 
Chapter 7 is word for word the 3rd published paper of this thesis on „MR-guided 
cardiac interventions using MR-safe passive devices: a preclinical study and first-in-man 
congenital interventions “, published in Circulation Cardiovascular Interventions in 2010. 
The pre-clinical animal study as well as the first two clinical patients that underwent 
interventional catheterisation procedures using sole MRI fluoroscopy are described in this 
publication.  
 
Chapter 8 describes the results of subsequent patients enrolled in the clinical trial and 




CHAPTER 3.  





Congenital heart disease occurs in 0.8-1% of children. A proportion of these patients will 
require interventional treatment in the form of cardiac catheterisation or surgery, whilst some 
will only require medical therapy. Echocardiography is the investigation of choice for 
diagnosis and follow-up of these patients, whilst magnetic resonance imaging (MRI) is now 
increasingly used in most centres as another non-invasive imaging modality to assess complex 
congenital cases and to answer specific questions, not possible to address with 
echocardiography. The complexity of congenital heart disease entities being treated today, as 
well as the surgical and interventional survival for congenital heart disease has generated 
questions and necessitated treatment options that were not available in the past. The treatment 
options and their success have made the paediatric cardiology community re-consider of how 
best to further investigate, treat and prolong further the survival and quality of life of these 
patients. Surgical correction of older patients that had been left untreated has been revisited, 
medical management optimisation with new drugs has become possible and questions such as 
resulting comorbidities (ie the risk of tumor formation) in multi-catheterised and multi-
investigated patients using X-Ray radiation have become relevant. For this reason, diagnostic 
cardiac catheterisations and CT scans have been replaced by cardiac MRI wherever possible.  
A new form of hybrid imaging (XMR) has also been introduced, which combines the 
use of both X-Ray and MR fluoroscopy during the performance of cardiac catheterisations. 
XMR can address clinical questions, such as estimation of pulmonary vascular resistance and 
cardiac output response to stress accurately, without the limitation of haemodynamic 
assumptions during calculations 
1-8
. In addition, when invasive pressure monitoring is 
required, the combination of MRI with cardiac catheterisation has also been used and proven 
to reduce the screening time and radiation dose 
1
. This is achieved by minimising the X-Ray 
screening to the absolute minimum in order to obtain information that cannot be otherwise 
obtained by the MRI scan, whilst questions of anatomy and function are left to be assessed 
with the MRI study.  
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Finally, beyond diagnosis, MRI nowadays expands its potentials in guiding 
interventional procedures that can be potentially performed in the MR scanner in a similar 
fashion and with similar equipment to the ones used in the traditional catheterisation suite. 
This chapter discusses in detail how magnetic resonance imaging can be used for 
interventional diagnosis and treatment in young children with congenital heart disease. 
 
 
3.2  MR-guided diagnostic catheterisations combined with X-Ray imaging 
 
In the current era, diagnostic cardiac catheterisations have been greatly replaced either by 
MRI scans or by combined MRI-cardiac catheterisation procedures (XMR catheterisation). 
The latter have been shown to entail lower radiation exposure doses as compared with 
controls 
2
, which is of particular importance in children with congenital heart disease, who are 
usually subjected to various and repetitive procedures involving radiation. According to the 
U.K. National Radiation Protection Board, the mean risk of solid tumor development as a 
result of a single cardiac catheterisation procedure is approximately 1 in 2500 in adults. This 
risk increases to 1 in 1000 in children if exposure occurs by 5 years of age 
9
. Also, the 
proportion of the body that is irradiated increases as the size of the patient decreases, and that 
coupled with the increased radiosensitivity of the young and immature tissues explains recent 
evidence showing that these children are at higher risk of developing cancer in later life 
10-12
. 
A further benefit of XMR guided catheterisations is the improved soft tissue 
characterisation and visualisation of cardiac structures and vessels, in contrast to X-Ray 
guided catheterisations, which rely on identification of landmarks and contrast angiography. 
XMR catheterisations also provide physiological data, that are not possible to obtain during 
X-Ray catheterisation and that are essential for the assessment of complex patients. Such data 
involve cardiac output assessment, accurate estimation of Qp:Qs, flows and maximum 
velocities across valves and in large vessels, pressure-volume loop relationships and 
ventricular function. 
13-19
 In addition, pulmonary vascular resistance and compliance can be 




XMR catheterisations take place in specifically designed catheterisation laboratories with 
combined X-Ray and MRI facilities (Figure 1-1) or in geographically adjacent cath lab and 
MRI suites. In our laboratory we use a 1.5T MR-scanner (Achieva, Philips, Best, Netherlands) 
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and a Philips BV Pulsera cardiac X-Ray unit. There are in-room monitor and controls, which 
can swing across both the bottom end and the top end of the magnet, and display MRI images 
and haemodynamic pressure traces (Figure 1-2). The fluoroscopic area and magnetic 
resonance field of an XMR laboratory can be separated either by doors or by a clearly defined 
line, demarcating the 5-gauss line of the magnet, beyond which it is possible for electronic 
devices, such as echocardiography machines and computer equipment, to be brought into the 
room (Figure 1-1). The tabletop design allows patients to be moved from one modality to the 
other in a very short time. Furthermore, the table position is stored within the system allowing 
image fusion between the MRI and X-Ray system or even fusion with other imaging 




After the patient is placed on the table in the non-magnetic area of the XMR room, the 
MRI coil and ECG leads are placed. MR compatible patient monitoring and anaesthetic 
equipment is used. For pressure monitoring, we use the commercially available 
haemodynamic monitoring system EP Tracer 102 (CardioTek B.V, Maastricht, Holland). All 
of the anaesthetic and monitoring tubing and lines are designed with extra length and are 
secured to the movable tabletop to ensure smooth patient transfer. The ECG and invasive 
pressure data are sent from the MR-compatible monitoring equipment via an optical network 
to a computer in the control room, where the cardiac technician is stationed. The appropriate 
measurement and recording of the data is made in the usual way. The technician has access to 
monitors that show the appropriate X-Ray or MR images of the procedure. Blood samples 
taken during the procedure are labeled in the room and passed to the technician in the control 
room. Monitoring of the cardiac rhythm during XMR catheterisation is achieved with a vector 
electrocardiogram (VCG). This is a QRS detection algorithm that automatically adjusts to the 
actual electrical axis of the patient’s heart and the specific multidimensional QRS waveform. 
This greatly improves the reliability of R-wave detection to nearly 100%. A reliable R-wave, 
with the P- and T-waves that are also always clearly seen with VCG, allows detection of 
nearly all arrhythmias. Unfortunately, there are no ECG systems that can reliably provide ST 
segment or T-wave morphologic information. In the future, using signal-processing 
techniques, it may be possible to improve ECG monitoring during MR scanning.  
Lastly, significant consideration has been given in the design, construction, and 
operation of our XMR facility with regards to safety, and a comprehensive safety protocol has 
been drawn up in our laboratory to minimize possible hazards (Table 3-1). 
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Table 3-1. X-Ray and Magnetic Resonance Facility: Safety Features 
 Compulsory safety training of all magnetic resonance interventional staff 
 Specially designed clothes without pockets 
 Safety officer restricting entry to the main room during XMR intervention 
 Clear demarcation of ferromagnetic safe and unsafe areas within the room 
 Magnetic-resonance-compatible anaesthetic and monitoring equipment 
 Noise-proof headphone systems for all staff within the room 
 X-Ray- and radiofrequency-shielded scrub room 
 Positive pressure air handling and filtration system 
 Tethering of all ferromagnetic equipment to the wall or floor 
 Safety checks whenever a patient is transferred between X-Ray and magnetic resonance to 
ensure that metallic instruments used for catheterisation are not taken across to the magnetic 
resonance end of the room 
 Written log of all safety infringements and regular review of safety procedures  
  
3.2.2 XMR catheterisation procedure 
The children are prepared in a similar fashion to the ones undergoing routine cardiac 
catheterisation. In our department, the patients are anaesthetised and recovered in a dedicated 
area adjacent to the MRI scanning area. They are wheeled into the MRI room on MR 
compatible trolleys and the procedure starts with cardiac catheterisation in the non-magnetic 
field area of the XMR laboratory. The facilities and equipment of the X-Ray area are similar 
to the traditional catheterisation laboratory. A non MR-compatible angiographic pump is 
brought into the laboratory and used for detailed angiography, when needed. Standard ECG 
leads are placed as well as a three-lead ECG attached to the anaesthetic machine and the 
VCG, to use for cardiac monitoring during MR scanning. The VCG electrodes are placed on 
the subcostal margin, outside the X-Ray field of view, and the VCG is used for triggering MR 
scans. An MR-compatible pulse oximeter and noninvasive blood pressure monitoring 
equipment are also attached. The exhaled anaesthetic gases are monitored for end-tidal carbon 
dioxide as well as the concentration of the volatile anaesthetic agents. Flexible phase array RF 
coils are used. These coils are relatively X-Ray lucent and thus do not need to be removed 
between MR and X-Ray imaging.  
After femoral venous and arterial access is obtained, a heparin bolus of 50IU/Kg is 
given with ACT monitoring. Once right and/or left heart catheterisation is completed under 
X-Ray guidance, the patient is moved across to the MRI scanner on the sliding table after the 
standard ECG leads are removed and safety checks have been performed. These include an 
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operating theater-style check of all metallic objects used under X-Ray. Once the patient is 
inside the scanner, a second drape is placed and then lifted up and taped to the top of the 
magnet, which in effect provides sterile draping of the bore and sides of the magnet (Figure 3-
1). MR-compatible catheters (Wedge catheter, Arrow, Reading, PA, USA) placed during 
fluoroscopic-guided cardiac catheterisation are left in situ, usually in the right ventricle or 
main pulmonary artery for continuous haemodynamic pressure monitoring. Invasive arterial 
pressure is monitored through a femoral arterial cannula or sheath. Simultaneous MRI phase 
contrast sequences or MR-cine scans with pressure recordings are performed. These give the 
physician a “snapshot” of the patient’s physiology at that particular time and reflect the 
conditions that they may have been subjected to (ie: nitric oxide administration during PVR 
assessment or dobutamine stress testing). In addition, a free breathing ECG-triggered three-
dimensional (3D) SSFP scan of the heart and great vessels and 3D contrast enhanced MRA 
are also performed to elucidate intracardiac and vascular anatomy. 
We have performed over 150 cardiac catheterisations for congenital heart disease in 
our XMR laboratory (published abstract: Tzifa A, Bell A. Cardiol Young; 2011). Some of 
these have involved combined X-Ray and MR-guided procedures, whilst others have been 
performed solely under MR-guidance. Most of the catheterisation procedures were performed 
for PVR measurement, while a number were performed to define anatomy, perform XMR-
guided interventions (Figure 3-2) or assess the cardiac output stress response to Dobutamine.     
 
 





Aortic stent implantation using the XMR guidance system. A magnetic resonance angiography image is 
superimposed onto the fluoroscopic image during stent implantation for native aortic coarctation with 
very tortuous aortic arch (a). A bespoke made covered CP stent was implanted across the coarctation in 
the X-Ray part of the XMR lab (b). Following stent implantation the patient was moved back to the 
scanner and a repeat MRI study showed good stent position and no areas of dissection. 
 
3.2.3 XMR catheterisation for assessment of pulmonary vascular resistance  
Pulmonary vascular resistance studies have been performed either with fluoroscopic or MR-
guidance. There is no age limit for the performance of these studies, but higher spatial 
resolution is required for phase contrast flow imaging in infants to ensure there are enough 
pixels covering the vessel of interest for accurate flow measurements. With the technique 
described above, the patient undergoes an MRI scan and phase contrast flow images are 
obtained in the MPA, RPA, LPA and aorta with simultaneous pressure monitoring. For 
patients with univentricular heart palliation, flows are assessed in the branch pulmonary 
arteries for PVR estimation, but also in the two caval veins, the neo-aorta (and native aorta, 
when of good size) for detailed assessment of the physiology and the flow distribution.   
When the PVR at baseline is raised, 100% FiO2 and nitric oxide 20ppm are given and 
the PVR is recalculated. It is important to obtain saturation/blood gas at the beginning of the 
procedure and during different stages of the protocol, as dictated by the patient’s clinical 
condition and end-tidal CO2. This is to ensure a steady anaesthetic state and normocarbia, 
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which is vital for accurate PVR measurement, as the latter can swing and be inadvertently 
elevated if the CO2 levels are allowed to rise. Our group has found moderate to good 
agreement between the Fick method and the MR method of deriving PVR at baseline 
conditions 
1
. However, in the presence of nitric oxide, which is used to assess pulmonary 
vasoreactivity, there was less agreement between the two methods. There was not only 
worsening in agreement but also a large bias when PVR was measured in the presence of 
100% oxygen and nitric oxide. We believe that this is the result of errors in the Fick method 
rather than the XMR method, which has important implications for patient management, 
particularly of young children. To this end, we suggest that PVR measurement in children is 
performed with the MR method wherever possible. 
 
3.2.4 XMR catheterisation for assessment of cardiac output response to stress  
MRI is the ideal tool for the evaluation of cardiac function and output. When combined with 
dobutamine stress it allows the measurement of RV function, LV function, cardiac output and 
cardiac output in response to stress and systemic vasodilation. Further to a full anatomical 
assessment, MRI cardiac catheterisation combined with dobutamine stress enables evaluation 
of the RV pressure compared to systemic, the RV systolic and diastolic function in response 
to stress, the gradient across the pulmonary valve or branch pulmonary arteries and the 
pulmonary artery pressure and pulmonary vascular resistance. If the PVR is elevated, 
pulmonary vasodilators can be administered and the patient’s PVR and haemodynamics are 
reassessed. Selective angiography can also be performed to address clinical questions, such as 
pulmonary arteriovenous malformations or abnormal collateral vessels that are not clearly 
visualised on MRI.  
Dobutamine stress study for assessment of the cardiac output response to stress is 
occasionally performed for clinical or research purposes in selected patients. Suitable groups 
are children with Alagille syndrome and pulmonary artery stenosis, patients after tetralogy of 
Fallot repair, or more rarely children with univentricular heart circulation (Published abstracts: 
Bellsham-Revell H; Tzifa A JCMR 2011).  
Our MRI with Dobutamine stress scan protocol is described as follows: We always 
ensure that the patient is not intravascular dry, as this may affect the cardiac output response 
to stress. After femoral venous and arterial access is obtained, a heparin bolus of 30-50IU/Kg 
is given with ACT monitoring. Right heart catheterisation is performed either with 
fluoroscopic or MRI guidance. Pressure measurements are obtained in the femoral artery, IVC, 
RA, RV, MPA, LPA (proximal and distal), RPA (proximal and distal), RPA and LPA wedge 
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or left atrium if an atrial communication is present. An MRI compatible catheter (wedge 
catheter, Arrow) is left in the RV and an MRI scan is performed. This includes a 4 chamber 
view, RVOT and LVOT views in two planes, Gad MRA, 3D volume SSFP scan, short axis 
stack (for LV and RV functional assessment), phase contrast flow images in the aorta and 
pulmonary artery (for assessment of cardiac output and shunt) and differential branch 
pulmonary artery flows. The PVR is obtained from PA flow measurement combined with 
direct pressure measurement, as described above. After baseline data are obtained, 
dobutamine is infused at 10 micrograms/kg/min and repeat short axis stack and phase contrast 
flows in the aorta and pulmonary artery are obtained. The infusion is then increased to 20 
micrograms/kg/min with repeat short axis stack and phase contrast flows in the aorta and 
pulmonary artery. We aim for a heart rate increase by > 50% from baseline. After all 
physiologic measurements have been obtained, the dobutamine infusion is discontinued and 
the patient is woken up and extubated. Children are observed on the ward for a few hours post 
anaesthetic and are usually discharged home the same day.  
 
Value of dobutamine stress studies in pre-liver transplantation patients.  
Our group have shown the value of dobutamine stress studies in patients with Alagille 
syndrome and branch pulmonary artery stenosis 
25
. It was concluded that patients with a 
maximal increase in cardiac output of less than 40% and or right ventricular/aortic pressure 
ratio of equal or greater than 0.5 should be considered at higher risk and were associated with 
less favourable outcome following liver trasplantation. This study was not performed in an 
XMR setting, but in the cardiac catheterisation laboratory, using a flow-directed 
thermodilution catheter and cardiac output calculations were performed on a dedicated 
computer (Vigalence, Baxter, Newbury, Berkshire, UK). In the current era, MRI can obtain 
the above calculations easily and with more precision, providing data on the ventricular 
function and volumes as well as flows across the great vessels, as described in Chapter 4 of 
this thesis in more detail. 
 
 
3.3 Solely MR-guided diagnostic cardiac catheterisations 
 
MR-guided cardiac catheterisations have been diagnostic in nature (in humans) and 
interventional (in animals). Visualisation has been aided by passive and active visualisation 
techniques and catheter tracking. Passive tracking technique is commonly based on 
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visualisation of susceptibility artifacts or signal voids caused by the interventional device 
under MR imaging, 
26-29
 whereas active catheter tracking and visualisation uses an electrical 
connection to the MR scanner, and localisation or tracking of the device requires the device 
itself, along with any additional hardware or software that comes with it. Typically, the device 





Active guidewires that have been used for MR-guided interventions in animals are 
tracked or visualised by employing miniature RF-coils or loopless antenna both connected to 
the scanner using a long metallic wire. This long wire can heat up during certain MRI 
sequences due to resonating RF waves. Despite modifications to reduce the risk of heating 
with active devices, under certain conditions heating at the tip can occur up to 70°C with 
obvious associated risks 
37
. New strategies for RF-safe active devices have been proposed 
including optical transmission and use of transformers to shorten the length of the conducting 
wire (Figures 3-3 and 3-4),
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 however no clinically safe active guidewires had been 
developed so far. Semi-active catheters use tuned fiducial markers that produce increase MR 
signal locally without wires connecting to the scanner 
40
. There are however issues with 
miniaturisation and the ability of firmly securing these markers to catheters. 
Passive devices, such as the ones used in our lab, have the advantage of no risk of 
heating and lower cost, but the disadvantage of being less visible than active guide wires and 
requiring manual tracking and changing of the imaging plane to keep the wire in view. To 
facilitate better and faster visualisation, the operators in our XMR laboratory use foot pedals 
(Figure 3-5). With those, the operator can start and stop the interactive scanning 
independently, and also adjust the imaging plane and slice position in order to get the 
interventional devices in view. The latter is achieved with the foot pedal function, which 
rotates through pre-selected imaging planes and the pedal pull/push action. 
At the beginning of any MR-guided catheterisation, the likely imaging planes needed 
for subsequent catheter tracking are stored along with the rest of the MRI protocol (Figure 3-
6). For example, for right heart catheterisation, the following views are stored: SVC/IVC 
saggital and coronal, 4-chamber, RVOT, R2CH, PA bifurcation, LPA saggital and RPA 
coronal views. The patients are placed on the X-Ray table, where sheaths are inserted after 
securing the chosen MRI coil and placement of the VCG leads. The patient is then moved into 
the scanner and the cardiac catheterisation is performed under sole MRI guidance (Figure 3-7). 
The in-room consol displays the haemodynamic pressures on one panel and four chosen 
imaging planes on the other (Figure 1-2). An interactive SSFP sequence (8 to10 frames/sec) 
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with real-time manipulation of scan parameters is used. The operators can start and stop the 
MRI scan independently with foot pedals and rotate through the four imaging planes 
displayed. The balloon wedge pressure catheter is inserted into the sheath in the right femoral 
vein and advanced into the inferior vena cava (Figure 3-8, 3-9). For this manoeuvre, a para-
saggital imaging plane, showing the inferior and superior vena cava and the right atrium is 
used. The balloon of the wedge pressure catheter is visualised as a dark signal void within the 
surrounding bright blood (Figure 3-8). As soon as the right atrium is reached, the imaging 
plane is interactively changed to show the right atrium and right ventricle from different 
projections (R2 chamber or 4-chamber view). The tricuspid valve is passed and the balloon 
wedge pressure catheter is advanced into the right ventricle. The imaging plane is then 
changed to show the outflow tract and then the main pulmonary artery. The catheter is 
advanced into both branch pulmonary arteries and the wedge position for detailed pressure 
measurements with pullback gradient recordings as necessary (Figure 3-9). Because only the 
tip of the wedge catheter is visualised, care is taken not to push the catheter too fast and thus 
beyond the MR imaging plane. This also ensures that the catheter does not accidentally form 
loops and possible knots. 
For left heart catheterisation, the balloon wedge pressure catheter is introduced via the 
femoral artery, inflated with CO2 and advanced through the descending aorta to the aortic arch. 
For this step a para-saggital imaging plane is chosen, which shows the aortic arch, the 
ascending aorta, the aortic valve and the left ventricle. The balloon of the wedge catheter is 
visible in the aorta as a signal void. Subsequently, the catheter is turned into the ascending 
aorta. For this, the use of an MR-compatible guidewire may be necessary, as the balloon 
wedge catheter at this point tends to travel up the head and neck vessels rather than down to 
the ascending aorta. Under MR-guidance it is then possible to cross non-stenotic aortic valves 
in order to measure LV pressure. If catheter manipulation into a particular heart chamber or 
vessel using MR guidance alone is difficult, the patient is transferred back to the X-Ray end 
of the room, where catheterisation can be continued under X-Ray fluoroscopy (e.g., to use a 
guidewire or a braided catheter). The patient can be transferred back to the MR scanner for 
further MR measurements once the catheter is positioned satisfactorily. The post- 
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Figure 3-3. 
Concept of the transformer-based cable for RF-safety: a) Transformers split a long cable into several 
short not resonant and thus RF-safe sections. b) Miniature transformer (diameter 1 mm) and coax-cable 
can be integrated into a catheter lumen. c) Tracking signal with high signal-to-noise ratio allows reliable 
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Figure 3-4.  
RF-safe catheter tracking in a pig experiment. The position of the micro-coil attached 
on the catheter tip is measured and displayed (cross) on real-time MR images (data 







Figure 3-5.  
Foot pedals are used to control the real-time MRI interface, e.g. to start/stop real-time MRI and to 
change between different pre-defined geometries. 
 
 
Figure 3-6:  
Planning and storing of imaging planes needed for subsequent visualisation of the MR-guided 





















Figure 3-7.  
Clinical MR-guided intervention. After 
positioning the patient on the XMR-table (a), 
the sheaths are inserted outside the MR-
scanner (b). The patient is then moved into the 
MR-magnet and the cardiac catheterisation is 
completely performed under MR-guidance (c) 
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Figure 3-8. 
The balloon of the wedge pressure catheter is visualised as a dark signal void within the 
surrounding bright blood in the IVC (a), right ventricle (b and c), right ventricular outflow tract (d), 







The balloon wedge catheter is advanced into both branch pulmonary arteries and 
pullback gradient recordings are taken as necessary from LPA distal (a) to LPA 
proximal (b) and RPA distal (c) to RPA proximal (d). 
 
 
3.4  Bridging between XMR-guided diagnostic and XMR-guided interventional 
procedures 
 
Hybrid approaches are becoming increasingly common in the management of congenital heart 
disease. Combining data from two or more imaging methods has the potential of targeting 
complex congenital heart disease in the best possible way, with reduced screening time and 
increased safety and efficacy.  
During our XMR catheterisations, image overlay has been used in selected cases, in a 
way whereby magnetic resonance angiography image has been superimposed onto a 
fluoroscopic image for better localizing and tracking of a pathological lesion (Figure 3-2). 
In congenital heart disease this has been particularly useful for hybrid imaging of aortic 
arch pathology. As part of this research thesis, eight patients with borderline aortic arch 
coarctation (native or re-coarctation) underwent MR-asssisted cardiac catheterisations to 
assess the anatomy but also measure gradients across the coarctation at rest and stress with 
Isoprenaline boluses (Published abstract: Valverde I;...Tzifa A...; Beerbaum P. JCMR 2011). 
In 6 patients conservative management was followed, whereas one patient underwent surgical 
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repair and one underwent percutaneous aortic arch stenting. This last patient had a complex 
aortic arch anatomy with severe tortuosity and needed stent implantation with a bespoke 
length stent of 6cm. Due to the high risk of the procedure it was decided to perform the 
intervention in the X-Ray area of the XMR lab, so that the MRI facilities could be used for the 
pre- and post- implantation assessment. The aortic stent was implanted using the XMR 
guidance system with simultanous image overlay, which provided us with more precision 
during stent placement (Figure 3-2). A magnetic resonance angiography image was obtained 
first with gadolinium bolus and was then superimposed onto the fluoroscopic image. The 
bespoke made covered CP stent was implanted across the coarctation in the X-Ray part of the 
XMR lab. Following stent implantation the patient was moved back to the scanner and a 




3.5 Bridging between solely MR-guided diagnostic and MR-guided interventional 
cardiac catheterisations: Test Occlusion Of Fontan Fenestration: Unique 
Contribution Of Interventional MRI 
 
Experience on solely MRI-guided diagnostic cardiac catheterisations and the precision of 
measured cardiac output changes obtained during those studies led us to further expand the 
potential of MR-guided cardiac catheterisation procedures. This is for example represented in 
the following published report of a 24-year old lady with fenestrated Fontan circulation who 
was referred for combined cardiac MRI and catheterisation procedure. The indication for an 
XMR study was to assess her anatomy and suitability for fenestration closure. The patient was 
considering pregnancy, however due to low saturations of 83%, successful pregnancy was 
unlikely.  
Under interactive screening, the balloon of a wedge catheter was inflated in the lateral 
tunnel to render it visible as a dark spot in the bright surrounding blood. The balloon was then 
deflated and advanced through the 4mm fenestration (Figure 3-10, Panel A) into the atrium. 
Atrial saturations measured 83% and aortic phase contrast flow images revealed cardiac 
output of 3.22 l/min. The balloon was then inflated against the atrial wall to completely 
obstruct the fenestration (Figure 3-10, Panel B). Repeat atrial saturations measured 96% and 
cardiac output decreased to 2.95l/min. Lateral tunnel and systemic pressures remained 
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unchanged. The minor drop of the cardiac output with the balloon inflated represented the 
contribution of the fenestration flow to the total cardiac output.  
Test occlusion of the Fontan fenestration must always be performed prior to 
interventional closure. In the catheterisation laboratory this entails measurement of the right 
atrial, left atrial and aortic pressures, mixed venous and aortic oxygen
 
saturations, 
measurement of whole-body oxygen consumption,
 





. However, these measurements can be laborious and prone 
to errors. This clinical case was representative of a more simplified method of assessing those 
patients, providing more accurate information on cardiac output changes with simultaneous 




Figure 3-10.  
Panel A: 3D SSFP coronal view of the lateral tunnel showing the Fontan fenestration jet. Panel 
B: Under interactive imaging, the balloon of the wedge catheter appeared like a dark circle in 
the surrounding white blood in the atrium (arrowhead). The balloon was kept inflated against 
the wall to obstruct the fenestration, whilst aortic phase contrast flows were performed to 







CHAPTER 4.  
 
Cardiovascular pre-operative assessment of children prior to liver 
transplantation using: combined Cardiac Catheterisation and 





Liver transplantation is occasionally required in children with Alagille syndrome (AS) and 
biliary atresia (BA). These liver diseases are associated with congenital heart disease in 85% 
and 15% of cases respectively and are associated with higher liver transplantation (LT) 
mortality and LT failure.  The increased transplant mortality may involve insufficient cardiac 
output reserve required to maintain adequate systemic blood pressure during and after liver 
graft reperfusion. Predictive features are peripheral pulmonary artery stenosis, right 
ventricular hypertension, high RV to femoral artery pressure ratio and low cardiac reserve 
during dobutamine stress 
25
. Our group has previously shown that LT mortality in children 
with AS is reduced if an increase in cardiac output of > 40% from baseline is induced by 
dobutamine stress, when cardiac output is estimated by cardiac catheterisation using the Fick 
dilution technique.  
Meticulous preoperative cardiovascular assessment is mandatory in children with CHD 
who are being considered for LT. This has been traditionally performed by echocardiography, 
and/or invasive cardiac catheterisation. Neither technique yields three-dimensional (3D) 
information, and may be limited by sonographic windows or poor soft tissue visualisation, 
whilst prolonged cardiac catheterisation procedures can be associated with high exposure to 
ionizing radiation. Furthermore, cardiac catheterisation alone may lead to an inaccurate 
calculation of the cardiac output and vascular resistance due to physiological assumptions 
3,4
.  
During this research work, we modified our catheterisation protocol for evaluation of 
pre-LT suitability 
25
, by replacing part of the X-Ray cardiac catheterisation procedure by 
magnetic resonance imaging (XMR).  
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4.2 Methods  
 
4.2.1 Patients 
Between June 2007 and May 2011, 17 children with liver disease were referred for invasive 
cardiovascular assessment as part of their assessment for LT (mean age and weight of 4.7±4.4 
years and 14.5±9.6 kg, respectively).  The diagnosis of liver disease was made on the basis of 
clinical, radiological and histopathological findings. The study was approved by the local 
institutional review board and informed consent for dobutamine-stress XMR investigation 
was obtained from all patients or guardians.  A total of 23 XMR investigations were 
performed. Six patients were found to have obstructive right heart lesions and underwent 
therapeutic cardiac interventions. XMR procedures were repeated after their anatomy was 
corrected. 
 
4.2.2 XMR Dobutamine stress protocol 
The XMR studies were performed in our combined MRI/cardiac catheterisation interventional 
suite (Figure 1-1). All patients underwent routine general anaesthesia. Three different 
conditions were used during the XMR examination: condition I (baseline, resting condition) 
and two stress conditions, condition II (dobutamine 10 mcg/kg/min) and condition III 
(dobutamine 20 mcg/kg/min). A steady state was achieved in all patients by 10 minutes in 
each condition and the following full set of measurements were recorded:  Invasive pressure 
measurements (RV, PA and FA), phase-contrast MRI flow (in the aorta and PA), 2D-cine 
volumetry (right and left ventricle), electrocardiogram, pulse oxymetry (SaO2) and end tidal 
CO2. Cardiac index (l/min/m
2
) calculations were performed using phase-contrast flow MRI 
measurements in the aorta and main PA and analysed using commercially available software 
(Extended MR Workspace version 2.5.3.1, Philips Medical System, Best, The Netherlands). 
Pulmonary vascular resistance index (PVRI) was calculated as PVRI = (PA pressure – PA 





Statistical analysis was performed by using SPSS software (version 18; Chicago, Ill). An 
ANOVA test was performed to evaluate the haemodynamic changes between the different 
conditions. A Pearson test was used to analyze the correlation trend. The receiver operator 
characteristic (ROC) curve of the baseline cardiac index and the maximal percentage increase 
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in cardiac index during dobutamine were performed.  Statistical significance was inferred at p 





Combined XMR was completed successfully in all 23 procedures.  A major complication was 
observed in one patient who developed transient ventricular fibrillation in condition III with 
dobutamine 20 mcg/kg/min; this reverted promptly to sinus rhythm after discontinuing the 
dobutamine infusion.  
Mean X-Ray screening time and radiation dose were 8.2±4.4 min and 2.2±1.9 Gycm2, 
respectively. The individual haemodynamic changes during dobutamine infusion are 
summarised in Table 2-1.  There was a significant increase in the heart rate, cardiac index, RV 
systolic, mean PA and mean FA pressures from baseline to maximal dobutamine (20 
mcg/kg/min) stress (p<0.05). The mean baseline heart rate (89±15 bpm) and cardiac index 
(4.3±1.3 l/min/m2) significantly increased (p<0.05) at each pharmacological condition.  This 
upward trend in the cardiac index can also be expressed as percentage (%) change above 
baseline; increasing from condition I (rest) to condition II (dobutamine 10 mcg/kg/min) by 
31.4% (p<0.05); increasing again from condition II to condition III (dobutamine 20 
mcg/kg/min) by 15.9% (p<0.05) and total increase from rest to the maximal stress change 
(irrespective of condition) of 48.1%, (p<0.05) (Figure 4-1). The RV/FA ratio significantly 
increased from condition I (0.52±0.18) to condition II (0.55±0.24) and again to condition III 
(0.65±0.26). We found a 48% increase of the mean cardiac index from rest to maximal stress 
state. In 9 of 23 XMR studies, the cardiac index did not rise to above a 40% threshold. 
However, these patients were already in a hyperdynamic state at rest according to published 
criteria 
42
 with a resting cardiac index of 5.1±1.1 l/min/m2 and a heart rate of 95±17 bpm. The 
relationship between the cardiac index at rest and its maximal % increase during dobutamine 
stress was analysed and plotted in Figure 4-2.  
 50 
 
Figure 4-1.  
Bar and line chart haemodynamic changes at rest and during dobutamine stress. 
The changes in the cardiac index (bars, units in left axis, standard deviation 
represented in error bars) and right ventricle to femoral artery ratio (RV/FA) trend 






Scatter-plot graph for baseline cardiac index (rest) and maximal change in the 
cardiac index during dobutamine stress. The correlation trend is also shown (dotted 
line). 
 51 
There was a significant strong negative correlation (Pearson correlation coefficient -
0.64, p<0.05), trend-line shown in Figure 4-2.  Those patients with higher cardiac index at rest 
state displayed less capacity to further increase the cardiac index at the maximal 
pharmacological stress dose.  The ROC curve analysis was performed to identify a threshold 
for the baseline cardiac index to predict the likelihood to increase in the cardiac index above 
the recommended 40%. From this analysis, if the resting cardiac index was already above 4.3 
l/min/m
2
, the predicted maximal increase in the cardiac index was unlikely to reach the 40% 
threshold with a sensitivity of 85% and a specificity of 90% (ROC, p<0.05). 
The response of the RV systolic, mean PA and mean FA pressures to increasing dose of 
dobutamine is detailed in Table 4-1.  
 

























103 (15) 5.5 (1.5) 56.3 (21.2) 25.4 (6.2) 66.2 (13.6) 0.55 (0.24) 
III: Dobutamine 
20mcg/kg/min 
129 (18) 6.0 (1.4) 65.5 (27.9) 26.6 (11.2) 66.6 (15.4) 0.65 (0.26) 
 
 
A significant change was found in all the previous parameters from rest to dobutamine 
20 mcg/kg/min (p<0.05). As a consequence, the RV/FA ratio significantly increased from rest 
(0.52±0.18) to dobutamine 10 mcg/kg/min (0.55±0.24) up to dobutamine 20 mcg/kg/min 
(0.65±0.26). 
Five patients unable to raise their cardiac output above the previously recommended 
level of 40% due to right heart obstructions underwent 6 interventions (transcatheter n=4, 
surgical n=1 and medical n=1) and were restudied with XMR post-intervention. All patients 
that underwent anatomical optimisation (balloon dilation or stent implantation in the RVOT 
and stent implantation in the branch pulmonary arteries) were capable of raising their cardiac 
index following physiological stress on repeat XMR catheterisation.  
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Overall 9 of 17 patients underwent successful LT (age 6.05.4 years, 16.812.6 kg).  
One patient was already in a hyperdynamic state at baseline (cardiac index (CI) =4.96 
l/min/m2) and despite not achieving the previously recommended risk threshold of >40% CI 





This study represents our modified protocol for evaluation of pre-LT suitability, by replacing 
part of the X-Ray cardiac catheterisation procedure by magnetic resonance imaging (XMR). 
In our previous publication 
25
, we showed that a maximal increase in cardiac output of less 
than 40% after dobutamine and/or RV/FA ratio of equal or greater than 0.5 are considered to 
be at higher risk for LT. In addition, pre-transplant cardiac intervention for main or branch PA 
stenosis should be considered prior to the LT procedure.  
Our practice incorporating MRI has been modified for two reasons:  
1. XMR provides accurate measurement of pulmonary flow and cardiac output changes, 
whilst simultaneously providing intracardiac blood pressure measurements in one 
sitting. Traditional paediatric cardiac catheterisation techniques for flow quantification 
are based on the Fick principle using thermo or indicator-dilution methods or the 
assumed or measured oxygen consumption. These techniques suffer from significantly 
reduced reliability from an accumulation of errors from multiple measurements and 
from the presence of intracardiac shunts in children with CHD 
3,4
. As an alternative, 
velocity encoded phase-contrast MRI, which has previously been shown to measure 
the cardiac output accurately 
15 
can be combined with invasive pressure measurement 
to derive accurate pulmonary vascular resistance values 
43
 and assess the patient‘s 
physiology with more precision. 
2. MRI gives us high definition imaging and 3D assessment of any anatomical lesions to 
be targeted and corrected prior to liver transplantation. This is particularly important in 
patients that require stent implantation in the branch pulmonary arteries, as MRI is the 
best investigation to plan the procedure in terms of number of required stents, 
diameters and awareness of neighbouring structures during stent implantation. 
The haemodynamic results of our study are consistent with the established 
pharmacological actions of dobutamine, with significant increases in the heart rate, cardiac 
index, mean PA pressure, mean FA pressures and RV/FA ratio. As shown in the negative 
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trend-line correlation (Figure 4-2), those patients with higher cardiac index at rest, probably 
reflecting the physiological consequences of the severity of their liver disease, displayed less 
capacity for a further increase at the maximal dobutamine dose. XMR evaluation at rest could 
therefore be used to predict the ventricular response to dobutamine stress. A resting cardiac 
index of > 4.1 l/min/m
2 
could predict an inability to increase the cardiac output by >40% 
during maximal pharmacological stress with a high sensitivity (85%) and specificity (90%).  
We hypothesise that for patients already in a high baseline cardiac output, it may not be 
physiologically possible to increase the cardiac output even further above the known 40% 
threshold 
25
. To this end, two children with high basal cardiac index at rest who were not able 
to increase the cardiac index by greater than 40% were nonetheless considered suitable for LT. 
Indeed one of these two cases underwent successful LT, whilst the other patient was removed 
from the transplant list due to improved clinical status.   
This is of course supplemental information to our initial statement regarding the 
suboptimal outcomes in patients with CO increase < 40%. To this end, further studies are 
required to confirm if children with a suboptimal increase in the cardiac index during 
dobutamine stress should be reconsidered for transplantation, specifically in the setting of 






The main limitation of this study is that it was not powered to determine whether patients with 
high cardiac output at baseline -and therefore inability to raise their cardiac output above the 
previously recommended level of 40%-, would still be suitable for transplantation. We 
hypothesise that this would be the case, but further studies with larger number of patients are 





We conclude that dobutamine-stress XMR is a feasible one-stop investigation for the pre-
operative assessment of children who are on the list for LT. The benefits of this hybrid 
method comparing with the routine catheterisation technique are: a) the provision of all 
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anatomical data necessary for planning the procedures required for the correction of 
anatomical obstructions and b) accurate evaluation of the cardiac reserve at rest and stress in 
order to assess the patient’s suitability for LT and evaluate the peri-transplantation risk 










CHAPTER  5.  
 
MR-guided cardiac interventions using MR-compatible devices: 





Although, MR-guided diagnostic catheterisations have been feasible without the use of a 
guidewire, transcatheter interventions nearly always require a suitable guidewire to aid and 
support the procedures. Standard guidewires, approved for X-Ray procedures, are 
manufactured from Nickel-Titanium superelastic memory alloys (Nitinol) or stainless steel. 
Due to the conductive properties of these materials and the length of the guidewire, 
radiofrequency (RF) coupling can cause significant heating of the material 
37
; hence metallic 
guidewires are not applicable for MR-guided interventions in patients.  
Since 2001 there have been a number of animal studies showing the safety and 
efficacy of interventional MRI (i-MRI) for a multitude of procedures that are currently 
performed under X-Ray guidance 
44-58
. In particular, i-MRI has been used to facilitate 





 as well as balloon angioplasty and stent implantation in coronary and carotid 
arteries 
49-53
, stenting of pulmonary arteries 
54
, stenting of aortic coarctation 
55,56
 and vena 
cava interventions 
57,58
. The procedures have been aided by the use of non MR-safe active 
guidewires and prototype or commercially available devices and were either solely MR-
guided or combined with conventional catheterisation before and after the procedure. 
The guidewires used for the above interventions were either active or passive. Active 
guidewires are tracked by in situ miniature RF-coils or loopless antenna both connected to the 
scanner using a long metallic wire. This long wire can have standing currents induced in it 
during certain MRI sequences, which can lead to heat generation. Despite modifications to 
reduce the risk of heating with active devices, under certain conditions heating at the tip can 
occur up to 70°C with obvious associated risks 37. Furthermore, active devices are more costly 
due to hardware modifications. New strategies for safe active devices have been proposed 
including optical transmission and use of transformers to shorten the length of the conducting 
wire 
38,39
, however, no safe active guidewires have been developed so far. Semi-active 
catheters use tuned fiducial markers that produce increase MR signal locally without wires 
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connecting to the scanner 
40
. There are however issues with miniaturisation and the ability of 
firmly securing these markers to catheters. Passive guide wires have the advantage of no risk 
of heating and lower cost, but the disadvantage of being less visible than active guide wires 
and requiring manual tracking and changing of the imaging plane to keep the wire in view.  
Left heart MR-guided cardiac interventions have also been performed without the use of a 
guidewire in the LV, in an animal model for transcatheter implantation of a prosthetic valve in 
the aortic valve position 
59
, where the use of susceptibility markers enabled precise position 
monitoring of the interventional instrument and in patients who underwent balloon dilation of 
aortic coarctation 
60
. In the last study, the procedures were performed in a pilot group of 5 
patients and were preceded and followed by conventional catheterisation to assess the arch 
angiographically and measure pressure gradients across the coarctation segment. A non MR-
safe guidewire was used for this purpose. The wire was withdrawn before the patient entered 
the MR scanner and another self-made non-metallic guidewire was advanced just up to the 
distal port of the balloon catheter and the procedure was completed under MR guidance. 
Although the desired result of procedural and haemodynamic success was achieved nearly in 
all patients without the use of a guiding wire for the valvuloplasty balloon, most teams 
performing congenital interventions would consider its use mandatory. This provides them 
with a railroad for catheters and interventional devices to track on, stability during the 
intervention but most importantly with security of being able to re-cross the lesion should that 
become necessary in the event of procedural complications. 
As derived from the above, the performance of MR-guided interventional procedures 
using a guidewire that is fully MR compatible and RF safe and has mechanical properties 
similar to the standard nitinol or stainless steel guidewires had not been possible to date. 
In order to facilitate the materialisation of such interventions, an MR-compatible and 
safe guidewire had to be manufactured. After years of research work a guidewire with the 
mechanical features of a standard nitinol guidewire was developed and proposed 
61
. This was 
the first guidewire that fulfilled all prerequisites to become a clinical device. The wire 
underwent robust testing as described below. Further to that, as a pre-clinical step, we used 
the guidewire in combination with already available MRI safe catheters in an animal model 




5.2 Assessment of the catheterisation equipment to be used in the MRI 
environment for the performance of transcatheter interventions 
 
5.2.1 Cardiac catheters 
Cardiac catheters should be non-braided in order to be used in the MRI environment. Swan-
Ganz (wedge catheters - endhole) or Berman (sidehole) [Arrow, Reading, PA, USA] have 
been used for the solely MRI-guided catheterisations in our department. Most frequent 
diameters have been the 4, 5 and 6 Fr. The 4Fr catheters are compatible with a 0.018 
guidewire, whilst the 5Fr are compatible with a 0.025 guidewire, hence they would not be 
suitable to be used for interventions with the proposed guidewire, which was 0.035’’. To this 
end, only 6 and 7Fr wedge catheters were suitable to be used as guide catheters for the MR-
guided cardiac interventions. 
 
5.2.2 Valvuloplasty balloons 
Similar to the cardiac catheters, valvuloplasty balloons should also be non-braided, and 
0.035’’ guidewire compatible, in order to be used in the MRI environment. The most 
frequently used valvuloplasty balloons for congenital heart disease (Tyshak valvuloplasty 
balloons, NuMED, NY, USA), commonly employed for balloon dilation of valves and 
vascular stenosis are non-braided, hence they could be safely used in the MRI environment. In 
addition, prior to the first-in-man clinical trial on MR-guided interventions, enquiries were 
made regarding other non-braided balloons and it was concluded that the Cristal balloons 
(Bard, Tempe, AZ, USA), do not have any inner braiding, hence they could also be used for 
valvuloplasties, angioplasties and stent implantations performed under MRI-guidance.  
 
5.2.3 MRI-compatible guide wire 
As mentioned above, the newly developed fibreglass guidewire 
61
 underwent robust testing in 
vitro prior to testing its performance in MRI-guided cardiac interventions in animals. The 
testing took place according to the American Society for Testing and Materials (ASTM) – 
(Appendix). 
The wire’s length was 220cm and the diameter 0.89mm. The guide wire consisted of a 
Microscale Pultrusion Material core, composed of fibers of different non-metallic materials, 
such as quartz. The core material was connected to a Nitinol radio opaque tip. It was coated 
with Polyvinylpyrrolidone, which is a commonly used hydrophilic coating material in medical 
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devices. The guide wires were sterilized with Ethylene Oxide and packaged sterile for the 
clinical trial.  
 
 




5.3 Assessment of the fibreglass guidewire to be used in the MRI 
environment for the performance of transcatheter interventions 
 
Robust assessment of the guidewire’s properties took place prior to its use in vivo. The 
essential requirements checklist demonstrating how the investigational device (fibreglass 
guidewire) complied with each of the relevant Essential Requirements, as well as the risk 
analysis are given in the Appendix. 
Below is a summary of the most vital testing that the wire underwent prior to getting 
approval by the UK Medicines and Healthcare Regulatory Authority (MHRA) as a new 
medicinal device. 
 
5.3.1 Mechanical strength Testing  
 
5.3.1.1 Testing method for bending stress  
In a bending assembly the guide wire was bended in 20 cycles around two cylinders 
with a diameter twenty times as tall as the guide wire. In addition, the guidewire was tested 
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for resistance against damage caused by bending. The testing assembly consisted of two 
pivoted cylinders with a diameter of 15 mm, which were mounted with a gap of two 
millimeters to a plate. Figure 5-2 shows the testing assembly. The guide wire was induced to 
the assembly and manually bended. This procedure was repeated 20 times in a sequence of 




Figure 5-2. Assembly for bending stress testing 
 
 
5.3.1.2 Testing method for resistance to breakage  
The coated guide wire was fixed to an assembly according to the DIN-norm. The guide 
wire was closely winded around a cylinder with a 10 times diameter of the guide wire. The 
testing assembly consisted of a cylinder with a diameter of 8 mm and a fixing unit with a gap 
of 9 mm to the cylinder. The diameters and the gap complied with the DIN-norm. Figure 5-3 
shows the principle of the testing assembly, figure 5-4 shows a guide wire after the testing 
procedure.  
The guide wire was clamped with the distal end at the fixing unit and winded with 8 
completed closely windings around the cylinder. No breakage of the guidewires was detected 
and only a slight buckling/bending of the guide wire could be observed (Figure 5-4), thus 












5.3.1.3 Testing method for tensile stress  
After the exposure of the test of bending and breakage the guide wires were tested for 
tensile stress. The guide wire was clamped to a weight of 2 kg and tested for tensile stress as 










This tensile test was repeated with the part, where the nitinol tip was glued to the rest 
of the guide wire (Figure 5-6). In this test the tensile stress on the wire was increased to 50 N. 









Figure 5-6. Tensile test of the fixing point between nitinol tip and guide wire 
 
 
5.3.2  ASTM testing of the MR guidewire: RF safety, MR image artifacts and  
magnetic interaction 
The guide wire was tested by Philips Research Laboratories (Dr Sascha Krueger) to the 
following ASTM Standards: 
1. ASTM F2182 - 02a: Standard Test Method for Measurement of Radio Frequency 
Induced Heating Near Passive Implants During Magnetic Resonance Imaging 
2. ASTM F2119 - 07 Standard Test Method for Evaluation of MR Image Artifacts from 
Passive Implants 
3. ASTM F2213 - 06 Standard Test Method for Measurement of Magnetically Induced 
Torque on Medical Devices in the Magnetic Resonance Environment 
 
The RF-safety and magnetic interaction of the novel MR guidewire was used in a clinical 
1.5T MRI scanner in comparison to a standard Nitinol reference guidewire. 
 
 63 
5.3.2.1 Material and Methods 
All tests were performed on a 1.5m long MR-guidewire as shown above and described 
in detail in the following: The MR guidewire features a base material with a diameter of less 
than or equal to 0.018’’ (i.e. 450-480µm) of pultruded fiber-reinforced plastic material. The 
Nitinol (SE_NT07_SULOX_0.400mm, @ Medical Technologies N.V., Herk-de-Stad, 
Belgium) tip section is 100mm long or shorter and shafted to the base (the diameter of the 
Nitinol part at the shaft is 450-480µm, the diameter at the tip is approximately 100µm). For 
passive MRI visualisation, continuous and homogeneous Fe-doping of the wire matrix (1% of 
matrix mass) + additional discrete markers (steel wire pieces, length = 2mm, diameter = 
50µm) every 100mm were used. A polymer jacket with biocompatible hydrophilic coating 
was used resulting in an outer diameter of at least 0.032’’ (i.e. at least approximately 800-
820µm).  
The MR guidewire was examined for RF safety referring to ASTM F2182-02a inside a safety 
phantom described therein in a 1.5T clinical whole-body Philips Achieva MR system.  
 
5.3.2.2 Simulations 
Electromagnetic simulations using MoM (Method of Moments) analysis of FEKO 
(FEKO, Stellenbosch, ZA) were performed to estimate the device-induced local SAR for the 
0.032’’ MR guidewire in comparison with a typical 0.032 Nitinol-based guidewire which 
served as a reference (Terumo RF 32 GA, Terumo Corp., Tokyo, Japan). To this end, a 
realistic whole-body quadrature transmit coil at 64MHz (1.5T) was simulated. The devices 
were simulated by a cylindrical model containing an inner part (mainly GFRP and only 10cm 
of Nitinol for the MR guidewire and a full-length Nitinol core for the Nitinol-based reference 
guidewire) and a polymer sheath of appropriate thickness and diameter. The Nitinol wire was 
simulated to be in resonant condition. Practically, a wire of a resonant length of ~90cm was 
used in the simulations. In a realistic situation such a resonant condition is typically met at a 
certain insertion depth of 50-100cm depending on the electrical condition of the proximal part 
of the wire. The patient was simulated as a dielectric cylindrical lossy medium (dielectric 
constant  = 81, conductivity  = 0.8 S/m). 
 
5.3.2.3 RF safety 
Additional experimental safety tests were performed on an ASTM phantom (ASTM-
2182.02). The details of the phantom were: Rectangular torso phantom morphology, >30 kg 
of tissue simulating phantom gel in basin, phantom gel composed according to ASTM 
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prescription (0.8 g/L NaCl + 5.85 g/L polyacrylic acid in distilled water (according to ASTM 
this results in a conductivity of ~0.8 S/m @ 64MHz, ~0.4 S/m @ 1kHz, Dielectric constant: 
60-100 @ 64MHz, Diffusion constant: 1.3 * 10-7 m²/s, Heat capacity: ~4kJ/(kg*K), high 
viscosity). 
Temperature measurements were performed as follows: A 15 min laboratory 
temperature measurement (21 +- 0.5)°C was performed. Subsequently, a 5 min phantom 
liquid measurement (21 +- 0.5)°C was performed (phantom liquid was stored for >24h inside 
RF-cage). For the actual heating measurements, an MRI-Sequence: T1W-FFE, TR = 3.5ms, 
TE = 1.65ms, flip = 50°, SAR = 3.9 W/kg (cf. also ASTM 2182-02a, section 8.6) was run on 
the scanner (the SAR calculation uses a patient weight of 30kg). This sequence has: B1rms = 
7.86µT, 1/TR = 286 Hz, B1max = 23.09µT. 
A Luxtron 790 optical temperature probe (as recommended in ASTM 2182-02a) was 
positioned to be in contact with the tip of the guidewire, where the strongest RF heating can 
be expected. A reference probe was positioned inside the phantom fluid at a distance 
of >100mm from the metallic tip part of the guidewire (Figure 5-7). 
The guidewire was placed at the largest possible off-isocenter position within the 
scanner bore. At large off center positions, higher electrical fields, and therefore, stronger RF 
heating are expected. Within the geometrical phantom boundaries, the positions of the 
positioning units were further optimized so that the Nitinol reference guidewire of the same 
length showed significant RF heating during the RF heating measurements as described below. 
 
5.3.2.4 MR image artifacts 
To obtain a realistic assessment of the image artifacts in-vivo, pig experiments were 
performed targeting e.g. renal and carotid arteries. Susceptibility-based image artifacts in MRI 
are strongly dependent on the MRI sequence and the local environment conditions such as e.g. 
blood flow, which effects convection of the dephased spins. Referring to ASTM F2119-01, 
the MRI image artifacts were investigated using the following typical interventional sequence:  
Cartesian balanced SSFP, TR = 4.2, TE = 2.1, slice thickness 5mm, Matrix 224x168, flip 
angle 35°.  
 
5.3.2.5 Magnetic interaction 
The magnetic torque was assessed referring to ASTM F2213-04: For the 
determination of the magneto-static torque of the device (m=2g, l = 1.5m) an accuracy of 1/10 
* g * m * l = 2.9 * 10
-3
 Nm is required.  
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Magnetically-induced displacement forces were assessed referring to ASTM F20520-
02.  
 
5.3.3 Results and Conclusion 
 
5.3.3.1 Simulations 
The local guidewire-induced SAR for the MR guidewire, positioned for strong RF-
coupling and therefore also RF heating, is a factor of 100 lower than for the Nitinol reference 
guidewire positioned identically. Of note is that this position may not even be the position of 
strongest RF heating for the Nitinol reference guidewire. To this end, the simulated SAR 
reduction yields a conservative estimation. There was an impression of significantly reduced 
local electrical fields for the MR guidewire compared to the reference guidewire.  
 
5.3.3.2 RF safety 
The reference probe in the phantom showed no measurable temperature changes during 
the 5 min period prior to the RF heating measurements. The Nitinol reference guidewire was 
brought into a position of strong RF heating as described above using the mentioned 
positioning units. A temperature increase by almost 5K/(2W/kg) was measured. During 
execution of the MR sequence, for the MR-safe guidewire, a maximum temperature increase 
of only (0.1-0.2)K / 2W/kg) was measured at the device tip in the described phantom setup. 
Note that the measurement resolution of the Luxtron system is 0.1K. This demonstrated a 
significant local SAR reduction and reduction of RF heating to less than 1K/(2W/kg) of the 
MR guidewire compared to the Nitinol reference guidewire.  
 
5.3.3.3 MR image artifacts 
Artifact size of tip in the described typical real-time balanced SSFP sequence used for 
interventional MRI procedures was 5-10mm. 
 
5.3.3.4 Magnetic interaction 
Magnetic torque: No torque could be resolved within the given accuracy. Magneto-
dynamic force was not applicable. Lorentz forces were not applicable as no currents were 
applied to the device.  
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Magnetically-induced displacement: No deflection could be resolved (<< 5°). It could 
be concluded that the magnetically–induced forces were much lower than the weight of the 
device. 
 
Figure 5-7. RF safety and magnetic interaction testing of the guidewire 
 





Positioning of the guidewire 




Positioning of the fiber–
optic temperature probe at 
the metal containing tip of 





Phantom filled with described 
phantom liquid with guidewire 
























RF -sa fe guidewire 
 
Temperature recordings for the 
MR guidewire (blue) and the 
Nitinol reference guidewire 
(red). 
 
marker a t 
guidewire tip
 
MR image artifact of a 
discrete tip marker 
(Cartesian balanced SSFP, 
TR = 4.2, TE = 2.1, slice 
thickness 5mm, Matrix 
224x168, flip angle 35°). 
 
Locally increased SAR hot spot 
for a typical 0.032’’ Nitinol 
reference guidewire. 
 
Significant reduction of local 
SAR levels for the 0.032’’ MR 
guidewire having only a 10cm 
long Nitinol tip section. 
 
 67 
5.3.4 Biological and Toxicological Safety of the guidewire coating 
The guidewire was coated with Polyvinylpyrrolidone (PVP), type Kollidon 90F. PVP 
is widely used as excipient / additive in medicine, pharmaceuticals, cosmetics and foods. It 
has been used as plasma expander since the 1940s, and is metabolically inert in rat, dog and 




I-labelled PVP [Appendix].  
The lubricious coating of the guidewires consists of PVP. The coating does not contain 
toxic additives. The solvents used for the coating procedure are non-toxic. After 
manufacturing, the coated guidewires are rinsed / incubated in pyrogen-free water 3 times (30 
min each), dried in a sterile flow over night, with the consequence of complete volatilization 
of the used solvents. No peeling / flaking off could be observed after drying, indicating 
stability of the coating. 
In summary, the biological / toxicological risks of the coating were regarded as very 
low. Even in the case of partial PVP abrasion during in vivo manipulation of the device, the 
risk would remain negligible due to the (documented) inertness of the coating. 
 
5.3.5 Guidewire coating strength and flaking 
The surface of the guidewires has a smooth appearance. The coating itself is barely 
visible, due to its transparency. No flaking or scaling-off of the coating could be observed on 
the guidewire, especially at the bendings, which occured after the breakage test (Figure 5-8). 
 
  
Figure 5-8. Guidewire coating strength and flaking assessment 
 
 
5.3.6 Wire sterilisation 
The guidewires were sterilised with Ethylene oxide. The sterilisation assessment 
proforma required by MHRA is given is Appendix. 
 68 
5.3.7 Instructions for use 
The guidewire’s instructions for use were produced prior to its use in the first-in-man clinical 
trial on MRI-guided interventions and are given the Appendix. 
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CHAPTER 6.  
 
MR-guided cardiac interventions using MR-compatible devices: 
Study protocol of the first-in-man clinical trial 
 
 
Prior to starting the first-in-man clinical trial on MRI-guided interventions a study protocol 




6.1 Background & Rationale 
 
Congenital heart defects are present in 6-8/1000 live births. For the majority of those the 
defect is minor, and either no treatment or a relatively straightforward procedure is all that is 
required. However, for a significant number of patients the cardiac defect is complex and 
requires surgical correction or transcatheter interventions through the major veins and arteries 
of the body or both. Up until now the transcatheter interventions have taken place in the 
catheterisation laboratory with the aid of fluoroscopy (X-Rays). This has two major 
drawbacks: a. poor visibility of the cardiac structures, as the interventions performed are 
based on angiograms taken following injection of contrast (dye) and b. the use of ionising 
radiation. Magnetic resonance imaging has become an increasingly important investigation in 
the diagnosis and management of congenital heart disease in recent years and has nearly 
completely replaced diagnostic cardiac catheterisations in institutions where it is available. 
Cardiac MRI is able to demonstrate with high-resolution the three-dimensional anatomy of 
complex cardiac abnormalities and in addition it is able to accurately determine the cardiac 
function and cardiac output. Moreover, when haemodynamic data (such as intracardiac 
pressures and oxygen saturations) are essential for the diagnosis and management of the 
patient, MRI-guided diagnostic cardiac catheterisations can be successfully performed, thus 
completely eliminating exposure to radiation. 
The department of Paediatric Cardiology at Guy’s and St Thomas’ Hospital has been 
at the forefront of the development of cardiac MRI in children with congenital heart disease in 
the United Kingdom with an MRI program that dates back to the late 1990s. This program has 
increased to the point that as a unit we now perform in excess of 330 MRI scans and 
approximately 40 MRI-guided diagnostic cardiac catheterisations in children and adults with 
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congenital heart disease per year. Since 2002 a program also exists for performance of cardiac 
interventions using combined X-Ray and MR guidance (hybrid XMR interventions). The 
reason for having to use radiation up until now was the unavailability of an MRI compatible 
guide wire, which is essential to guide the cardiac catheters to certain places in or outside the 
heart and also provide a rail track for the interventional equipment (balloon catheters and 
balloon/stent assemblies) to travel on. Such an MRI compatible guidewire was recently 
developed, as described above, hence planning of the first in man study of completely MRI-
guided congenital cardiac interventions took place. In addition to elimination of radiation 
exposure and improved visualisation of the target lesion, which can be of particular help in 
complex lesions with rotated anatomy, performance of the interventions under MR imaging 
would enable us to assess the end result by obtaining an MRI scan at the end of the procedure 
(ie: for quantification of valvar regurgitation following balloon dilation of a valvar lesion). 
 
 
6.2  Trial Objectives, Design and Statistics 
 
6.2.1 Trial Objectives 
The study’s primary end point was to show the safety and efficacy of the MRI compatible 
guide wire, ie: to show that we would be able to perform the identical procedure to the X-Ray 
guided intervention without additional complications or adverse events related to the wire.     
The secondary end point was the successful reduction of pressure gradient across the 
target stenosed lesion (>50%) for which the intervention was going to be performed 
 
6.2.2 Trial Design & Flowchart 
This would be the first in man single arm interventional device trial. The study time scale was 
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6.2.3 Trial Statistics and Sample Size 
It was planned that twenty patients fulfilling the inclusion and exclusion criteria would be 
recruited. As this was going to be a feasibility study we looked at similar studies previously 
reported in the literature and the figure of approximately 20 patients had been used to 
demonstrate feasibility of new techniques to guide cardiac catheterisations.   
 
6.2.4 Analysis 
This was going to be a non randomised trial In order to assess the primary outcome measures 
we planned to perform a descriptive analysis.  
For the secondary outcome measures we were going to use age and procedure- matched 
historic controls and compare the percentage of success under the 2 methods. Interventional 
success would be defined as improvement in the degree of stenosis from pre- to post 
intervention of > 50% as measured by pull back pressure difference. 
 
 
6.3  Selection and Withdrawal of Subjects  
 
6.3.1 Inclusion and exclusion Criteria  
It was decided to recruit patients above 2 years of age with specific cardiac lesions, such as 
valvar aortic and pulmonary stenosis, branch pulmonary artery stenosis and aortic coarctation. 
The age limit was set as such, because patients above 2 years of age were more likely to 
require balloon diameters above 14mm, which were compatible with 0.035 guidewires.  
Inability to provide informed consent and contraindication to undertake an MRI scan (ie: 
because of pacemaker implantation, renal failure) would exclude patients from the trial. 
Patients would not be excluded on grounds of disability, gender, race, religion or belief or 
sexual orientation. 
 
6.3.2 Withdrawal of Subjects  
Subjects would be withdrawn from the study if there was a change in their clinical status that 
rendered them unable to have an MRI scan (ie: pacemaker implantation, development of renal 




6.3 Assessment of Efficacy  
 
Assessment of the efficacy parameters would be performed by a. haemodynamic 
measurement of pressure gradients and b. performance of a brief MRI study to assess the 
degree of improvement across the target lesion and associated regurgitation (where applicable) 
and also by an echocardiogram, as routinely performed, to assess the interventional result. 
Primary efficacy parameter was set as the performance of the identical procedure to the X-
Ray guided cardiac intervention without additional complications or adverse events related to 
the wire. Secondary efficacy parameter would be the reduction of pressure gradient across the 
target stenosed lesion for which the intervention was being performed by more than 50%. 
 
 
6.5 Assessment of Safety  
 
6.5.1 Specification, Timing and Recording of Safety Parameters  
Before having an MRI scan all participants would be taken through the safety checklist by the 
researcher or clinician. This would preclude anyone with contra-indications to MR (e.g. 
pacemakers) from participating.   
Unlike most medical imaging modalities, MRI does not use ionising radiation but 
instead generates images using magnetic fields and radio waves. MRI equipment is 
manufactured according to international safety standards (IEC 60601-2-33) to ensure that this 
imaging process does not have adverse effects on patients or volunteers. However, there are 
certain ‘indirect’ hazards, primarily the presence of a powerful magnet, which will exert 
strong forces on ferromagnetic objects brought close to the scanner. Rigorous safety policies 
are in place to minimise these risks, including local rules and training procedures that meet 
the requirements of the MHRA ‘Safety Guidelines for Magnetic Resonance Imaging 
Equipment in Clinical Use’ (2007 edition). MRI has been carried out on tens of thousands of 
patients and volunteers at Guy’s and St Thomas’ over a period of more than 20 years without 
a serious adverse incident. However, should an adverse events occured, it would be recorded 
and monitored to ensure it would not lead to an adverse reaction. 
 
6.5.2 Procedures for Recording and Reporting Adverse Events 
During study preparation we sought advice from expert staff working in the NHS Trust and 
the College. Approval of the device for the purpose proposed was sought and obtained from 
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the Head of Magnetic Resonance Imaging Physics of King’s College London and a Senior 
Scientist from Medical Physics of Guy’s and St Thomas’ Hospital. A comprehensive and 
effective system was set in place for the reporting of any wire-related adverse incidents. This 
would be done in accordance with the MHRA bulletin no 3 on “Guidance on the operation of 
the EU vigilance system in the UK” and the MHRA device bulletin on reporting adverse 
incidents and disseminating medical device alerts.  
 
 
6.6. Ethics & Regulatory Approvals 
 
The trial was set to be conducted in compliance with the principles of the Declaration of 
Helsinki (1996), the principles of GCP and all of the applicable regulatory requirements. The 
Research and Ethics Committee to which the study protocol was submitted was the King’s 
College Ethics Committee, which assesses regularly protocols relating to new medical devices 
(Appendix). In addition, an application was made to the UK Medicines and Healthcare 
Regulatory Authority (MHRA) for approval of the new medicinal device (MR compatible and 
safe fibreglass guidewire). Approval of the new medicinal device was granted by MHRA in 
November 2009 and the clinical trial was commenced a month later. In the following chapter, 
which is word for word our publication in Circ Cardiovasc Intervent, we describe in detail the 




CHAPTER 7.  
 
MR-guided cardiac interventions using MR-safe passive devices: a 





Diagnosis and treatment of patients with congenital heart disease has improved considerably 
over the past few decades, with more patients surviving into adulthood and more complex 
operations and interventions being performed across all age groups. Whilst echocardiography 
or MRI can easily assess cardiac anatomy and function, haemodynamic pressure 
measurements can only be performed invasively, mainly under X-Ray guidance. However, 
the use of radiation during repetitive X-Ray guided catheterisation has led to concerns relating 
to the risk of solid tumours in later life 
62,63
, and that is particularly true in children in whom 
increased radiosensitivity, coupled with the possibility of repetitive exposure to diagnostic 
and interventional X-Ray procedures, can lead to a significant increase of cancer risk 
10-12 
. 
In contrast, MR-guided diagnostic cardiac catheterisations involve no exposure to 
radiation and are currently established in some centers as their preferred method for 
assessment of pulmonary vascular resistance in children and adults 
2,22,64
. As well as 
providing haemodynamic data, MRI-guided catheterisation procedures provide useful 
additional information, such as detailed delineation of the cardiac anatomy, flows across 
valves and in large vessels, pressure-volume loop relationships and ventricular function, 
leading to more accurate and informed treatment stratification and assessment of outcome. 
Furthermore, real-time visualisation of the cardiovascular structures in any required spatial 
orientation, and more detailed additional information obtained from 3D MRI scans, can be of 
particular benefit in patients with complex congenital heart disease.  
Although, MR-guided diagnostic catheterisations are feasible without the use of a 
guidewire, catheter interventions nearly always require a suitable guidewire to aid and support 
the procedures. Standard guidewires, approved for X-Ray procedures, are manufactured from 
Nickel-Titanium superelastic memory alloys (Nitinol) or stainless steel. Due to the conductive 
properties of these materials and the length of the guidewire, radiofrequency (RF) coupling 
can cause significant heating of the material,
37
 hence metallic guidewires are not applicable 
for MR-guided interventions in patients. 
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Continuous development of software and hardware has allowed the application of 
interventional MRI in animal models for many procedures currently performed under X-Ray 
guidance and for the in vivo monitoring of catheter-based vascular gene delivery 
65-67
. 
However, some of the guidewires used in these studies, have not been proven to be RF safe,
66
 
whereas other RF safe polymer guidewires have not been found to conform mechanically to 
norms and do not provide adequate support for the interventional procedures 
67, 68
. Overall, 
there have been no interventions in an animal model to date using a guidewire that is fully 
MR compatible and RF safe and has mechanical properties similar to the standard nitinol or 
stainless steel guidewires used in the X-Ray cardiac catheterisation laboratory. As a result, 
none of the above promising approaches for MRI-guided interventions had been translated so 
far into the clinical setting. An MR-safe guidewire with the mechanical features of a standard 
nitinol guidewire was developed and proposed recently 
61
.This is the first guidewire that 
fulfils all prerequisites to become a clinical device with both actual safety proof and norm-
conforming mechanical properties.  
In the present study we report a. the pre-clinical assessment of the guidewire’s 
behaviour when guiding and supporting MR-compatible catheters and valvuloplasty balloons 
for MR-guided interventions and b. the first-in-man MR-guided congenital cardiac 






7.2.1.1 Guide wire 
A non-metallic MR-compatible and safe guide wire (MR-GW) with features, properties 
and safety characteristics as described previously was used for all interventions 
61
. The core of 
the MR-GW consists of an MR-safe glass fibre-compound and is produced using micro-
pultrusion leading to a compound fibre with excellent flexural and torsional stiffness and 
improved kinking properties as compared to polyetheretherketon-based (PEEK) MR guide 
wires proposed previously 
68
. A 10cm long cone-shaped Nitinol tip section is attached distally 
to provide superelasticity, higher flexibility and to allow shaping of the tip. The compound 
material is doped with iron at a concentration of 1% of the effective matrix mass to provide 
MR visibility over the full length. For accurate localisation of the tip, additional tiny iron 
splints of 50µm diameter and 2mm length are affixed along the distal 10 cm of the MR-GW 
PEEK 
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every 2cm, and then every 5cm for the next 30cm. A biocompatible hydrophilic coating 
(Lubriteq , Hemoteq AG, Würselen, Germany) covers the jacket to reduce blood clotting and 
to ensure proper gliding within catheters and vessels. The diameter of the MR-GW is 0.032’’ 




Balloon wedge pressure catheters (Arrow, Reading, PA, USA) were used for right and 
left heart catheterisation and to approach the target lesions. The balloon of the wedge catheter 
was filled with CO2 and was passively visualised as a dark circular signal void in the bright 
blood pool on the SSFP images.
69
 Commercially available, MR compatible valvuloplasty 
catheters (Tyshak II, NuMED, Hopkington, NY) were used for balloon dilation of the great 




7.3. Pre-clinical animal study 
 
Five female domestic pigs were included, as approved by the government committee on 
animal experiments. All interventions were carried out under general anaesthesia at the 
University Hospital Aachen, Germany. The new MR-GW was used to aid balloon dilation of 
non-diseased pulmonary and aortic valves, aortic arch and branch pulmonary arteries. Each 
procedure was carried out twice in each animal and performed by two different operators out 
of a group of three experienced interventionalists (AT, GK and RR). Invasive pressure 
monitoring was not performed as there were no stenotic lesions and the main interest of the 
study was to assess the behaviour of the guidewire.  
All interventions were performed on a clinical 1.5 T interventional MR system (Achieva, 
Philips, Best, Netherlands). Interactive real-time MR scanning was used to monitor the 
motion of the devices.  
For right heart catheterisation the balloon wedge pressure catheter was advanced into 
the inferior vena cava and inflated with 1.25 ml of CO2, making it clearly visible as a dark 
signal void within the surrounding bright blood (Figure 7-1). The catheter was then advanced 
to the right ventricle (RV), main pulmonary artery (MPA) and right pulmonary artery (RPA) 
and the wire was introduced. The different spacing of the iron-splints on the wire allowed 
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visual assessment of the wire length into the branch pulmonary artery (Figure 7-1). The 
balloon valvuloplasty catheter was introduced over the wire. In order to increase its visibility 
and facilitate correct positioning, 1 ml of Gd-DTPA (Magnevist, Beyer-Schering, Berlin, 
Germany) diluted in saline (1:10) was injected into the balloon. After placing it across the 
pulmonary valve, it was manually inflated up to 2 Atm and the pressure maintained for 5 
seconds. With the wire in a stable position wedged into one of the pulmonary arteries, the 
valvuloplasty catheter was advanced into a branch pulmonary artery and balloon dilation was 
performed.  
For left heart catheterisation the balloon wedge pressure catheter was first advanced into 
the descending aorta (Figure 7-2). The tip of the guidewire was shaped to a hook 
configuration and the guide wire advanced via the catheter into the aortic arch. Subsequently, 
the catheter and the guidewire were advanced into the ascending aorta and the aortic valve 
was crossed. The balloon valvuloplasty catheter was manually inflated with diluted Gd-DTPA 
at a sustained pressure for 5 seconds. With the wire in a stable position in the left ventricle, 
the valvuloplasty balloon was withdrawn to a level distal to the left subclavian artery and 





Figure 7-1.  
Dilation of a pulmonary valve in a swine. The images show the CO2 filled wedge catheter as a dark spot in 
the inferior vena cava (1), the right atrium (2), the right ventricle (3) and the main pulmonary artery (4,5). 
The guidewire was inserted into the catheter and advanced into the right pulmonary artery (6). Note that the 
in-between distance of the inferior 3 arrows represents the 2 cm distance between the iron oxide markers. 
The balloon wedge catheter was exchanged for the valvuloplasty catheter and advanced to the pulmonary 
valve. The balloon was inflated with diluted Gd-DTPA (7 and 8 asterisk) and the pulmonary  






Figure 7-2.  
Dilatation of the aortic valve and arch in the swine. The CO2 filled wedge catheter is seen in the descending 
aorta (1), with the wire advanced into the ascending aorta (2, open arrows: guidewire) and into the left 
ventricle. The valvuloplasty catheter is inflated across the aortic valve (3) and distal to the left subclavian 
artery (4). 
 
7.4 Clinical first-in-man congenital cardiac interventions 
 
Ethical approval for the performance of MRI-guided interventions for adults and children 
with congenital heart disease was obtained by an expert UK based device research ethics 
committee. Inclusion criteria for patient participation in the clinical trial were: simple 
congenital intervention, such as pulmonary or aortic valvuloplasty, ballooning of branch 
pulmonary artery or aortic arch or pre-implanted stents in the above positions, and age > 2 
years old. The new MR-GW was assessed and approved by the UK Medicines and Healthcare 
Products Regulatory Agency (MHRA). The first-in-man procedures were performed at the 
Evelina Children’s Hospital, St Thomas’ Hospital, London, UK. The procedures were 
performed under general anaesthesia, as per our routine practice for such congenital cardiac 
interventions in our hospital.  
Two patients with pulmonary valve stenosis underwent MR-guided balloon dilation of 
their pulmonary valves.  The first patient was a 6-year-old boy, who had progression of valvar 
pulmonary stenosis (PS) with peak echocardiographic gradient of 63 mmHg. Following 
informed consent the parents opted for the MR-guided interventional study. The second 
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patient was a 43-year old man with valvar and subvalvar pulmonary stenosis and severe right 
ventricular hypertrophy. Doppler Echocardiography revealed double envelope, indicating 
both valvar and subvalvar pulmonary stenosis and a peak gradient of 110mmHg. Both 
patients had an intact septum, were fully saturated and were clinically asymptomatic. 
The procedures were performed on an interventional 1.5T MR-scanner (Achieva, 
Philips, Best, Netherlands) in our combined X-Ray/MRI laboratory with the X-Ray 
equipment readily available for emergency bailout if required. We used the commercially 
available haemodynamic monitoring system EP Tracer 102 (CardioTek B.V, Maastricht, 
Holland) for haemodynamic pressure monitoring. The haemodynamic traces were displayed 
on one of the 2 panels in the mini in-room console, with the other panel displaying the i-MRI 
sequences. The operator could start and stop the interactive scanning independently using foot 
pedals, which also facilitated the adjustment of the imaging plane and slice position in order 
to get the interventional devices in view.  
Cannulation of the femoral vessels was performed at the beginning of the procedure and 
the patient was moved into the MRI scanner. For both patients the same scan protocol with 
similar scan parameters were used (Table 5-1), except for a higher spatial resolution used in 
the paediatric case. Following a plan-scan and sense reference scan, 2D SSFP cine MRI 
sequences were performed to assess the valve lesion. An ECG-triggered, free-breathing 3D 
SSFP scan and 2D quantitative phase contrast flow scans (Table 7-1) were used to measure 
the lesion size and maximum flow velocity through the lesion. 
The common imaging planes for catheter guidance were identified and stored. Balloon 
visualisation was facilitated with injection of Endorem 5% (for the adult patient) and dilute 
Gadolinium 1:10 (for the paediatric patient) into the balloon lumen. Cine and phase contrast 





Clinical case 1 (Paediatric): MRI assessment of the pulmonary valve revealed bicuspid 
pulmonary valve (BPV) with diameter of 22x22mm and effective orifice area of 49mm
2
. A 
6Fr wedge catheter was used for right heart catheterisation and to cross the pulmonary valve. 
Baseline haemodynamic gradient between the RV and MPA was 44mmHg. The wedge 
catheter was advanced to the distal LPA and the MR wire was introduced through the catheter 
to the distal vasculature and visualised on the sagittal view with the iron splints easily visible. 
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We observed no artifacts caused by the iron markers on the wire. A 22mm Tyshak balloon 
was initially used and inflated for 5sec. The waist seen on it was completely abolished (Figure 
7-3). Repeat pressure measurement revealed mild gradient improvement to 30mmHg, hence a 
25mm Tyshak II balloon was inflated across the valve as previously. Repeat gradient 
assessment showed further improvement to 25mmHg. No further attempts on inflating the 
pulmonary valve with a bigger balloon were made, due to the bicuspid nature of the valve and 
the fact that balloons bigger that 25mm would be inappropriately big for a child of this age. 
Repeat cine MRI assessment revealed increase of the effective orifice area on of the 
pulmonary valve from 49 to 92mm
2
. Phase contrast flow images showed no valvar 
regurgitation before and mild valvar regurgitation after the procedure (regurgitant fraction of 
7%). The total catheterisation time was 110min and total procedure time with the pre- and 
post-procedure MRI was 200min. 
The procedure was well tolerated by the patient who was woken up immediately after 
and was transferred to the cardiac ward 30 min later. Peak echocardiographic gradient as 
assessed the following morning had improved from 63mmHg prior to the procedure to 






 Dilatation of the pulmonary valve in a paediatric patient. The valvuloplasty balloon (asterisk) was inflated 
with diluted Gd-DTPA and the pulmonary valve was dilated. 
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Clinical case 2 (Adult): The patient had known valvar and subvalvar pulmonary stenosis, 
hence it was decided to alleviate the valvar component and reassess the subvalvar gradient at 
later stage. MRI assessment of the pulmonary valve revealed valve diameter of 21x24mm. In-
plane phase contrast flow images showed maximum velocity across the pulmonary valve and 
the sub-valvar lesion of 3.1m/s and 2.3m/s, respectively. A 6Fr wedge catheter was used. The 
catheter was advanced into the LPA and then in the LPA wedge position. The MR compatible 
guidewire was advanced through it and its position was confirmed on the LPA saggital view, 
where the iron markers were easily visible. The catheter was then withdrawn and a 23mm 
Tyshak II balloon was advanced over it. Visualisation of the balloon was achieved with 
injection of 1ml of 5% Endorem in the balloon lumen. After correct positioning was 
confirmed, a full inflation was performed on the saggital RVOT view (Figure 7-4). Repeat 
pressure measurement did not reveal significant haemodynamic improvement, hence a 25mm 
Tyshak balloon was chosen and inflated across the pulmonary valve. RV pressure at the end 
of the procedure remained systemic due to infundibular collapse, as evidenced on the 
haemodynamic trace and the phase contrast flow images. Velocity across the valve and sub-
valvar lesion was 2.5m/s and 2.6m/s, respectively. Gradual pullback from the MPA to beneath 
the pulmonary valve and then to the RV revealed a gradient of 17mmHg across the pulmonary 
valve and 60mmHg across the infundibular stenosis, confirming our initial suspicions that a 
significant subvalvar component was going to be present at the end of the procedure. The total 
catheterisation time was 80min and total procedure time with the pre- and post-procedure 
MRI was 170min. 
Peak echocardiographic gradient prior to the procedure was 110mmHg with double 
envelope trace (indicating valvar and subvalvar stenosis), which improved to 70mmHg after 
the procedure with change of the Doppler pattern from double to single envelope. The patient 
was commenced on b-blockade with propranolol, in an attempt to induce infundibular 
relaxation, until such time that the RV hypertrophy regressed sufficiently as a response to the 
valvar stenosis relief. No complications were noted and he was discharged home the 
following day. Repeat echocardiography 2 months after the procedure revealed further RVOT 





Figure 7-4.  
Dilatation of the pulmonary valve in an adult patient. The CO2 filled wedge catheter appears as a dark spot 
in the right ventricle, (1) main pulmonary artery (2) and the left pulmonary artery on the saggital view (3). 
The course of the guidewire with its iron markers is seen on the saggital view of the IVC/RA junction (4) 
and from the RV into the left pulmonary artery (5). The valvuloplasty balloon was inflated with 5% 






Since 2001 there have been a number of animal studies showing the safety and efficacy of 
interventional MRI for a multitude of procedures that are currently performed under X-Ray 
guidance.  
In particular, animal interventional MRI has been used to facilitate procedures such as 
creation or closure of atrial septal communications 
44-47
, intracoronary imaging 
48
 as well as 
coronary and carotid artery interventions 
49-53





, and vena cava interventions 
57,58
. The procedures have been aided by the use 
of non MR-safe active guidewires and prototype or commercially available devices and were 
either solely MR-guided or combined with conventional catheterisation before and after the 
procedure. 
Active guidewires are tracked or visualised by employing miniature RF-coils or 
loopless antenna both connected to the scanner using a long metallic wire. This long wire can 
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heat up to 70°C due to resonating RF waves 37. New strategies for safe active devices have 
been proposed including optical transmission and use of transformers to shorten the length of 
the conducting wire,
38,39
 however no safe active guidewires have been developed so far. Semi-
active catheters use tuned fiducial markers that produce increase MR signal locally without 
wires connecting to the scanner.
40
 There are however issues with miniaturisation and the 
ability of firmly securing these markers to catheters. Passive guide wires have the advantage 
of no risk of heating, but the disadvantage of being less visible than active guide wires and 
requiring manual tracking and changing of the imaging plane to keep the wire in view.  
MRI guided cardiac interventions have also been performed without the use of a 
guidewire, in an animal model for transcatheter implantation of a prosthetic valve in the aortic 
valve position 
59
, and in patients who underwent balloon dilation of aortic coarctation, using a 




Translation of the animal MR-guided interventions in humans had not been made 
possible to date due to the lack of fully MR compatible equipment. Recently an MR-safe 
guidewire fulfilling all prerequisites to become a clinical device has been developed. As a pre-
clinical step, we used this guidewire in combination with already available MRI safe catheters 
to perform solely MR guided cardiac interventions in an animal model and then performed the 
two first-in-man congenital cardiac interventions. The interactive scanning parameters were 
optimised to improve temporal resolution to 11-12 frames/sec (Table 7-1). Similar frame rates 
are used for X-Ray fluoroscopy in other institutions, particularly in longer procedures as a 
way of reducing X-Ray radiation dose. We used an 8-10mm thick imaging slice, hence the 
iron oxide markers within that slice were easily visualised. For the part of the wire outside 
that imaging slice we manually moved left and right of the current imaging slice by using the 
foot pedals, while the wire position was kept constant. During manipulation of catheters and 
balloons over the wire a key-imaging slice, which showed most of its length was imaged in 
real time with particular attention being paid to the iron oxide marker to ensure wire stability. 
During the balloon dilation we could visualise the valve and subvalvar area as well as the 
pulmonary artery, while under X-Ray we would only see the balloon, hence structural 
visualisation was much superior compared to X-Ray.  
Our first patient had a bicuspid pulmonary valve, a very rare congenital entity 
encountered in only 0.05-0.1% of the population 
70-72
. Although complete abolition of the 
balloon waist was achieved, there was still some residual pulmonary stenosis gradient at the 
end of the procedure, which was attributed to the bicuspid nature of the valve. The patient’s 
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haemodynamic gradient was reduced by 43% and his peak echocardiographic gradient by > 
60%. Our second patient was complicated by dual pathology with valvar and subvalvar 
pulmonary stenosis. Haemodynamic and MRI assessment at the end of the MR-catheterisation 
procedure revealed that the valvar gradient was now negligible. The RVOT gradient 
decreased by 60% on echocardiogram.  In both patients we deliberately undersized the 
balloon, which should have been 120-150% of the pulmonary valve annulus, due to the 
interventions being the first two in the trial, hence a more conservative approach was followed. 
The contrast material used to facilitate better visualisation of the valvuloplasty balloon 
differed between the paediatric and the adult case. This was due to the fact that the iron oxide 
agent Endorem, which would have been our preferred choice across all ages due to its 
superior visualisation properties, is not currently licenced for children and we would only use 
it in patients > 18 years of age. Endorem is used in adults for MR imaging of the liver. The 
intravascular dose used in these patients is 0.075ml/kg of the 0.2mmol/ml concentration. If 
Endorem was to be used for liver imaging in our adult patient who weighed 60kg, the 
recommended dose would have been 4.5mls. We used an Endorem concentration of 5%, and 
the absolute dose of 1 ml, hence even if the balloon burst, the total dose of endorem that 
would reach the circulation would have been well below the dose that is used in clinical 
practice. 
We have been encouraged by the successful outcome of our first two clinical cases, but 
we need to evaluate the feasibility, safety and efficacy of the MR-guided interventions further. 
To this end, a clinical trial on MR-guided cardiac interventions for commonly encountered 
lesions, such as aortic and pulmonary valve stenosis, branch pulmonary artery or aortic arch 
stenosis or dilatation of stents previously implanted in those vessels is ongoing. A committee 
has been set up to assess the safety and clinical outcome of the interventions. We hope that in 
the future MR-guided interventions will replace some cardiac catheterisation procedures 
performed in patients with congenital heart disease. The option of performing such 
interventions in the MRI suite is particularly appealing due to the lack of radiation, additional 
physiological data obtained and soft tissue characterisation. The latter is of particular 
relevance in interventional procedures, as real time i-MRI is hoped to offer early recognition 
and response to complications such as vascular rupture 
56
 or impending cardiac tamponade
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, 







The study is small but a clinical trial is underway. The catheterisation procedure times were 
long and the performance of an MRI before and after the intervention has added significantly 
to that time. We hope that the procedure time will shorten after our initial learning curve. The 
spatial and temporal resolution was acceptable to the operators in this study but we are 
working on further improving it for future interventions. 
In conclusion, we have demonstrated the feasibility of MRI-guided cardiac 
interventions using an MR-compatible guidewire. Future study is needed to determine 




Table 7-1. MR-scan parameters of the patient scans for the assessment of function, 
anatomy, angiography, flows and intervention 
 
Scan Type Patient 1 (6 years) Patient 2 (42 years) 
Function - 2D/M2D Cine Res.: 1.7x1.7x8 mm
3
 
SENSE = 2 
SSFP-contrast 
TR/TE =  3.2/1.6ms 
Flip-angle = 60 




SENSE = 2 
SSFP-contrast 
TR/TE = 3.0/1.5ms 
Flip-angle = 60 
Heart phases 40 
Breathhold 15s 
Anatomy – 3D whole heart Res.:1.3x1.3x1.3 mm3 
SENSE = 2 
SSFP-contrast 
TR/TE = 4.9/2.4ms 
Flip-angle = 90 
T2-prep TE=35ms 
TFE-factor=20 
ECG trigger: diastole 
Free-breathing, resp. 
gating window= 3mm 





SENSE = 2 
SSFP-contrast 
TR/TE = 4.7/2.3ms  
Flip-angle = 90 
T2-prep TE=35ms 
TFE-factor=28 
ECG trigger: diastole 
Free-breathing, resp. gating 
window= 3mm 
Scan time 3.4min (100% 
efficiency) 
Angiography – 3D MRA Res.:1.8x1.8x1.8 mm3 
SENSE=2 
T1-contrast 
TR/TE = 4.1/1.3ms 







TR/TE = 3.5/1.1ms 
Flip-angle = 40 
Single breathhold 
Flows – In/through-plane 2D-PCA Res.: 1.6x1.6x6 mm3 
SENSE=2 
T1-contrast 
TR/TE = 4.7/ 2.9 






SENSE = 2 
T1-contrast 
TR/TE = 4.3/2.6 
Flip-angle = 15 
VENC=380cm/s 
 





TR/TE =  2.5/1.1ms 
Partial Echo 
Half-scan=0.62 
Flip-angle = 45 






TR/TE =  2.4/1.0ms 
Partial Echo 
Half-scan=0.62 
Flip-angle = 45 






TR/TE =  2.6/1.3ms 
Flip-angle = 45 





CHAPTER 8.  
 





In total, seven patients aged 3 - 64 years were recruited in the clinical trial. Five patients 
underwent successful interventions for pulmonary valve stenosis (n=4) and native aortic 
coarctation (n=1). One patient with left pulmonary artery stent underwent right heart 
catheterisation with the aid of the new MR-wire, but the gradient across the stent was minimal, 
hence no intervention was required. The last patient (8 year old child) with severe aortic 
stenosis had an unsuccessful attempt at balloon dilation of the aortic valve, due to the inability 
of turning the wedge catheter into the ascending aorta, as the balloon of the catheter kept 
being pushed back by the aortic stenosis jet. This patient was then referred for X-Ray guided 
balloon dilation of the aortic valve. 
Catheter manipulations were monitored with real time MRI sequence with interactive 
modification of imaging plane and slice position. Temporal resolution was 11-12 frames/sec. 
Median procedure and catheterisation times were 180 and 110 min, respectively. All patients, 
except for the last, were discharged home the day after the procedure with > 50% reduction of 
the stenosis gradient and no procedural complications.  
   
 
8.2 Details of further patients enrolled in the clinical trial 
 
The first two patients enrolled in the clinical trial are described in Chapter 7. We hereby 
provide the clinical and procedural data of the remaining patients in the trial. 
 
Clinical case 3: A five-year-old patient with an antenatal diagnosis of possible coarctation 
was followed up for progressive aortic arch stenosis. The gradient acrossed the stenotic 
isthmus had increased to 60mmHg over time and therefore she was listed for a transcatheter 
intervention. Through a 7Fr sheath a 6Fr wedge catheter was inserted and advanced above the 
CoA. The position of the catheter was tracked by keeping the balloon at its tip inflated. Once 
the catheter was above the CoA, its tip was attempted to turn into the ascending aorta but this 
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proved unsuccessful, even when the wire was used to guide it. Eventually, the MR guide-wire 
was positioned in the left subclavian artery and its location was confirmed on the coronal 
plane under real-time interactive MRI. The arch measurements were assessed using black 
blood imaging. The transverse arch measured 12mm, the area above and below the CoA 
14mm and the descending aorta 12mm. The isthmus appeared tight with a diameter of 3-
4mm. 
With the wire in good position in the left subclavian artery, the wedge catheter was 
withdrawn and a 14mm Tyshak II balloon was advanced over it. Visualisation of the balloon 
was achieved with injection of 1ml of 5% Endorem in the balloon lumen. After correct 
positioning was confirmed, a full inflation was performed on the saggital plane. A waist was 
clearly seen, which was abolished completely. The stenotic area at the isthmus improved from 
a diameter of 3-4mm to 9mm (Figure 8-1). Repeat MRI after the intervention revealed a tiny 
flap at the ductal aspect. 
The total catheterisation time was 40min and total procedure time with the pre- and 
post-procedure MRI was 110min. 
Peak echocardiographic gradient prior to the procedure was 60mmHg, which improved 
to 30mmHg after the procedure and 20mmHg at follow-up 18months later. No complications 
were noted and the patient was discharged home the following day. He remains well 2 years 




Figure 8-1.  
Black blood imaging showing the coarctation at the isthmal area. On the right hand panel repeat black 
blood imaging after balloon dilation of the CoA reveals normal arch anatomy with no residual coarctation 
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Clinical case 4: A 65 year old patient with known valvar pulmonary stenosis, after pulmonary 
valvotomy at the age of 6 years underwent an MRI scan 2 months prior to the MRI-guided 
catheterisation, which showed extremely dilated LPA and vascular tree, possibly consistent 
with pulmonary hypertension in the left lung. She also had valvar pulmonary stenosis with 
borderline gradient of 38mmHg. It was decided to catheterise her, assess the pulmonary artery 
pressures and resistance and perform an MR-guided balloon valvuloplasty, if clinically 
appropriate. Under MR interactive scanning, the wedge catheter was advanced through a short 
groin sheath to the RA and RV. Isoprel was given for gradient assessment. The RV pressure 
was found to be suprasystemic at stress. The wedge catheter was then advanced to the MPA 
and LPA. The LPA pressure and left lung PVR were normal. The MR-compatible wire was 
then introduced and wedged distally in the LPA. The wedge catheter was exchanged for a 
25mm Tyshak II balloon. Visualisation of the balloon was achieved with injection of 1ml of 
5% Endorem in the balloon lumen. After correct positioning was confirmed, a full inflation 
was performed on the saggital RVOT view. 
Two inflations did not seem to produce any waist. Repeat gradient assessment revealed 
no pressure difference. Given that the valve had measured about 24mm both on 
echocardiogram and MRI assessment, the valvuloplasty balloon was upsized to 30mm and 
inflated across the valve. Repeat gradient assessment with and without isoprenaline confirmed 
good result with pullback gradient between MPA and RV of 20mmHg. The total 
catheterisation time was 120min and total procedure time with the pre- and post-procedure 
MRI was 230min. 
No complications were encountered and the patient was discharged home the following 
day. Echocardiogram at discharge showed an eccentric RVOT jet with gradient of 24mmHg.  
 
Clinical case 5: A 3.5yr old boy with tetralogy of Fallot and bicuspid PV was diagnosed with 
significant valvar pulmonary stenosis 2.5 years after Fallot repair and concurrent anterior 
commisurotomy intraoperatively. He was well clinically, but was noted to have an increasing 
gradient across the pulmonary valve of 66mmHg. 
During the MR-guided procedure, a wedge catheter was advanced to the right atrium, 
right ventricle and right pulmonary artery. The gradient across the pulmonary valve was 
30mmHg. Based on echocardiographic and MRI measurements, the pulmonary valve was 
dilated with a 14mm Tyshak II, but this did not reduce the gradient, which was remeasured to 
be 29mmHg. The balloon was upsized to a 16mm Tyshak II and the valve was re-ballooned. 
A balloon waist was clearly seen on interactive MRI, which was completely abolished. Repeat 
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pressure measurements showed a transvalvar gradient of 18mmHg. In order to assess the 
residual gradient at stress 2mcg of isoprenaline were given. The right ventricular pressure 
only rose to 2/3 systemic and hence the procedure was terminated.  The total catheterisation 
time was 120min and total procedure time with the pre- and post-procedure MRI was 220min. 
No complications were noted. The patient remains well 2 years after the procedure with 
laminar flow into the pulmonary artery and minimal pulmonary regurgitation.  
 
Clinical case 6: An eleven-year-old girl with unoperated partial AVSD and previous LPA 
stenosis, which had been stented at the age of 1 year, was scheduled for cardiac 
catheterisation prior to surgical repair and balloon dilation of the stent if it was found stenosed 
during catheterisation. MRI just prior to the MR-guided catheterisation showed good-sized 
branch pulmonary arteries of the same diameter, approximately 10mm. The LPA stent 
appeared patent on the black blood images (Figure 8-2). Differential flows between the two 
lungs showed flow to the right lung of 59% and left lung 41%. With a wedge catheter the 
pressures in the right ventricle and the branch pulmonary arteries were obtained. An attempt 
was made to cross the LPA stent with the wedge catheter, but it was not successful, hence the 
stent was crossed with the aid of the MR-compatible wire. Equal pressure gradient across the 
distal pulmonary arteries and the MPA was obtained of approximately 20mmHg. The overall 
Qp:Qs was 1.5:1. The pulmonary vascular resistance was moderately raised at 3.9WU.m
2 
with 




, respectively. No intimal 
proliferation was noted inside the stent and hence no intervention was performed. The total 
catheterisation time was 40min and total procedure time with the pre- and post-procedure 
MRI was 180min. The patient proceeded with subsequent corrective surgery successfully. 
 
  
Figure 8-2. Black blood imaging shows patent LPA stent both on the axial and sagittal views 
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Clinical case 7: The last patient enrolled in the clinical trial was an eight-year girl with VSD 
and arch hypoplasia, which had been repaired at the age of 1 month. She also had aortic 
stenosis due to bicuspid aortic valve, the severity of which had progressed significantly over 
the past few years. When the gradient across the aortic valve increased to 60mmHg she was 
listed for a transcatheter intervention.  
Through a 7Fr sheath a 6Fr wedge catheter was inserted and advanced to the level of 
the left subclavian artery. With the aid of the wire, the catheter was attempted to turn into the 
ascending aorta but without success as the balloon of the catheter kept being pushed back by 
the aortic stenosis jet. To this end, it was decided to exchange the short sheath for a long 
Mullins sheath, which would be placed in the ascending aorta in order to provide stability for 
the wedge catheter and better alignment for the guidewire to cross the valve. 
During sheath exchange, the long sheath was difficult to follow the wire at the groin 
and it was considered that access was lost. The procedure was ended and the patient returned 
to the catheterisation laboratory for fluoroscopic-guided valvuloplasty a few weeks later.  
Immediately after screening it became apparent that there was a fine guide wire in the 
aorta extending up to the right carotid (Figures 8-3 and 8-4). A brief attempt was made to 
snare it in the mid descending aorta where it appeared to end. Closer observation revealed a 
minimally opaque section and then more wire extending down to the right femoral artery 
where the difficulties were encountered in the MRI lab. The attempt at snaring it ended when 
it became clear that the wire was extravascular for a significant portion (Figure 8-5). Snaring 
it from the carotid end was considered to be too risky for breakage and embolisation, hence it 
was left it in situ. The carotid was widely patent in multiple views and after consultation with 
the vascular surgical team it was decided to leave the guide wire in place and not attempt 
surgical extraction of it. The patient subsequently had a successful X-Ray guided aortic valve 
balloon valvuloplasty without any complications. A few months later, the patient started 
having recurrent short episodes of cerebral transient ischaemic attacks. At that point it was 
decided to remove the guidewire surgically, which took place uneventfully via a left 
thoracotomy. 
The clinical trial was discontinued after the complication in this last patient and the 
adverse event was reported to the Regulatory Authority.  Although robust testing regarding 
wire fracture had been performed during the pre-clinical trial period as outlined in Chapter 5, 
(and further presented in the Appendix), it was concluded that the fibreglass guidewire was 
prone to breakage when direct force was applied. To this end, it was considered unsafe to 
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continue using this particular guidewire in the MRI environment and the clinical trial was 
discontinued.  
Other limitations encountered during the clinical trial were occasional suboptimal 
visualisation of the fibreglass wire, particularly at its nitinol tip and also poor steering around 
vascular curves and going around the arch to the ascending aorta, such as in clinical case 3 
described above and also the last study patient. Artifacts from the iron markers were not 
encountered and the frame rate of 11-12 frames/sec obtained during interactive screening was 




Figure 8-3.  
CXR of the patient prior to the balloon valvuloplasty procedure shows the fractured 








Figure 8-4.  
X-Ray fluoroscopy of the patient in the catheterisation lab shows the fractured  
guidewire extending up the right carotid and next to it a standard guidewire  





Figure 8-5. Femoral angiogram with the fractured guidewire in view, partially externalised 
outside the vessel.  
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8.3 Final discussion and future directions 
In our institution combined MRI and cardiac catheterisation (hybrid XMR) studies, and also 
solely MRI-guided diagnostic cardiac catheterisations have been performed since 2002, with 
the aim of reducing the radiation exposure and acquiring all of the required anatomical and 
physiological information in one sitting.   
The research work described in this thesis aimed at expanding the applications of 
XMR and MRI-guided diagnostic cardiac catheterisations and, most importantly, set the path 
towards materialisation of the first-in-man solely MR-guided interventions for congenital 
heart disease. Transcatheter cardiac therapeutic interventions prior to this research work had 
never become possible in humans, due to the lack of MRI compatible and safe cardiovascular 
equipment, mainly guidewires that are used for catheters, valvuloplasty or angioplasty 
balloons and for stents to travel on. 
During this research work, preclinical assessment of a newly manufactured MRI 
compatible and safe guidewire was performed and cardiovascular interventions were 
performed on 6 animals (swine). Following approval by the UK Medicines and Healthcare 
products Regulatory Authority and the assigned Ethics committee the first in man solely MR-
guided transcatheter cardiac interventions were successfully performed. 
Several difficulties and limitations were encountered during materialisation of percutaneous 
paediatric interventions under MRI guidance. At the beginning of the interventional MRI 
programme we increased the number of diagnostic MRI-guided catheterisations in order to 
acquaint ourselves with catheterising without direct fluoroscopy. The duration and technique 
of catheterisation under MRI-guidance differed to an extent in comparison with the X-Ray 
fluoroscopy guided catheterisations. The shaft of the wedge catheter would for example some 
times loop back on itself and despite it being advanced outside the body we could not see the 
CO2 filled balloon being advanced. In these cases we would have to withdraw the catheter, 
even outside the body and start advancing the catheter again. The inability of visualising the 
shaft of the catheters has been a major disadvantage and one that would increase at times the 
duration of the procedure. In addition, the nitinol tip of the MRI compatible guidewire was 
not visible, despite adapting and changing the slice orientation. To this end, we often had to 
make an assumption of its peripheral position.  It was also not possible to shape and curve the 
body of the wire, hence its inability to turn around the aortic arch. In two patients that took 
part in the clinical trial, one with native aortic coarctation and a second one with severe aortic 
stenosis this was a significant disadvantage and the second of these patients had to have the 
procedure completed under X-Ray fluoroscopy. The inability to screen the wire down the 
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groin during sheath exchange in the last patient, made it also difficult to prevent the 
complication observed.  
Median procedure and catheterisation times for MR-guided interventions were 180 and 110 
min, which was longer than the equivalent X-Ray guided procedure. Communication amongst 
staff was occasionally difficult due to the noise produced during interactive scanning. 
However, this was bypassed by good case preparation and having clearly defined roles in the 
team, who all knew well the steps of the procedure.  
Another limitation of the MR-guided procedures is the occupational exposure to 
radiofrequency. In the MRI environment there are various magnetic fields present (high static 
field, gradient field and radio frequency field). When a measurement setup was developed for 
simultaneous measurements of gradient magnetic fields and magnetic fields generated by 
motion of the body in static fields and the values were compared to reference levels given by 
the International Commission on Non-Ionizing Radiation Protection (ICNIRP), the exposure 
significantly exceeded the reference levels in positions where the medical personnel could 
have access during interventional procedures 
74
.  
 The pioneering research of our group and the extension of it towards materialisation of 
the first-in-man MRI guided intereventions (
2, 75-78
 and published abstracts 1-6) opened the 
horizons for further studies and attempts on optimising the equipment and sequences available 
to be used in the MRI environment and therefore bypass the limitations mentioned above. 
Indeed, in the past decade there is a very strong interest in the cardiovascular community in 
interventional MRI research 
79
. Beyond the passive catheter tracking and navigation (used in 
our research work), and the active catheter tracking, researchers have also used magnetic 
catheter steering, whereby the catheter has a coil at its tip and can be deflected for easier 
navigation 
80,81
. Magnetic catheter steering relies on a magnetic moment created by 
application of an electrical current to copper coils on the catheter tip, which results in 
alignment of the catheter in the direction of the Bo ﬁeld and may be found to be more helpful 
in assisting MR-guided interventions in the future.  
Recent work by the NIH group has demonstrated the feasibility of real-time MRI-guided right 
heart catheterisation in adults using passive catheters 
82
. The MRI cathetererisation procedure 
times were comparable with the X-Ray procedure times. The gadolinium-filled, rather than 
air-filled balloons seemed to be more conspicuous and therefore more effective in steering 
round to the target lesion. In addition, “passive” commercial MRI needles that are visualised 
based on intrinsic material properties have been used to access the pericardium or the cardiac 
cavities directly. Beyond the passive MRI needle, an investigational “active” antenna-needle 
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has also been used 
83
. Both passive and active needles may enable more sophisticated non-
surgical treatments for structural heart disease, including direct transthoracic implantation of 
large appliances and valves into the heart, non-surgical access and closure of large 
transthoracic cardiac access ports and enhanced image guidance of peripheral artery 
interventions such as recanalization of total chronic occlusion 
84-86
.  
Stent placement, valvar replacement, atrial septal defect closure, radiofrequency 
ablation and local gene cell delivery have all been shown to be feasible under sole MRI 
guidance in animals 
44-58
, whilst balloon valvuloplasty and angioplasty became possible in 
humans 
77
. Further availability of MR safe and compatible devices is essential for the success 
of invasive cardiovascular procedures performed under MRI-guidance and interactive 
visualisation of ablation lesions
 87
.  
In addition to the MRI-compatible and safe equipment being developed, novel imaging 
sequences have also emerged. A novel flow visualisation method, called virtual dye 
angiography has been developed recently in order to facilitate blood flow visualisation 
immediately and interactively in selected regions, analogous to selective catheter angiography 
88
. Normal or pathological communications between specific heart chambers and vessels can 
be seen in this way. Phase-contrast velocity mapping would not be suitable for this purpose as 
it requires too much data and is not capable of determining directly if blood originating in one 
location travels to a nearby location. Virtual dye angiography uses two-dimensional radio 
frequency pulses to achieve interactive, intermittent, targeted saturation of a localized region 
of the blood pool. The flow of the saturated spins is observed directly on real-time images or, 
in an enhanced manner, using ECG synchronized background subtraction. The modular nature 
of the technique allows for easy and seamless integration into a real-time, interactive imaging 
system. 
With the new MRI sequences being developed, that are targeted to serve real-time MRI 
procedures, and the emergence of new appropriate equipment, MR-guided procedures are 
expected to become less costly, far less invasive, faster and radiation-free. This may influence 
patient recovery and hospitalisation times. 
XMR procedures in the meantime continue to have a very important role in the 
diagnosis and management of patients with congenital heart disease.  The recent availability 
of a new hybrid system with side-by-side 1.5T magnet and C-arm X-Ray, may lead to more 
usage of the MRI as an interventional tool for the assessment and guidance of cardiac 
interventions.  
In summary, interventional MRI either as sole-MRI guidance for percutaneous 
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procedures or as hybrid XMR procedures has many benefits to offer, from minimising 
radiation and providing imaging with great anatomical detail to facilitating analysis of 
complex physiology in patients with congenital heart disease. A big step forward has been 
achieved by materialising the world-first percutaneous cardiovascular interventions in patients 
with valvar or vascular stenosis. Further work continues in the field in our department and 
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APPENDIX   
 
RF-safe guidewire essential requirements checklist 
Risk analysis 
Technical information on Soluble Kollidon 
Wire sterilization proforma 
Wire instructions for use 
Research Ethics Committee approval 
Guy’s & St. Thomas’ Hospital Trust R & D approval 
MHRA approval 
Patient information leaflet 
Children’s information leaflet 
Information for parents of children undergoing cardiac catheterisation 
Clinical trial consent form 
 
CONTRACT MEDICAL INTERNATIONAL 
   ESSENTIAL REQUIREMENTS CHECKLIST 
 




ECO-00985/TF-0018 FILE NAME:  MR Safe Guide Wire 
 









Location of Documents: 
Comments: 
I.  GENERAL REQUIREMENTS      
1. The device must be designed and manufactured in 
such a way that, when used under the conditions 
and for the purposes intended, they will not 
compromise the clinical condition or the safety of 
patients, or the safety and health of users or, where 
applicable, other persons, provided that any risks 
which may be associated with their use constitute 
acceptable risks when weighed against the benefits 
to the patient and are compatible with a high level 
of protection of health and safety. 
  RK-031 Risk 
Management 




ISO 14971:2007 – 
Medical Devices – 




CMI SOP ENG-007 
“Risk Analysis 
Procedure” 
Risk Management Section of 
Technical Dossier Body TF-0018 
 
Risk Management File in Risk 
Management Attachment of 
Technical Dossier TF-0018 
Manufacturing 
Flow Chart 




CMI Inspection Specs. 
 




Manufacturing Flow Chart 
Attachment of Technical Dossier 
TF-0018 
 
Design Master Record 










Section of Technical Dossier TF-
0018 
CONTRACT MEDICAL INTERNATIONAL 
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Location of Documents: 
Comments: 
2. The solutions adopted by the manufacturer for the 
design and construction of the devices must 
conform to safety principles, taking account of the 
generally acknowledged state of the art. 
In selecting the most appropriate solutions, the 
manufacturer must apply the following principles 
in the following order: 
 eliminate or reduce risks as far as possible 
(inherently safe design and construction), 
 where appropriate take adequate protection 
measures including alarms if necessary, in 
relation to risks that cannot be eliminated, 
 inform users of the residual risks due to any 
shortcomings of the protection measures 
adopted. 
  RK-031 Risk 
Management 





Use of MR Safe 
Guide Wire 
ISO 14971:2007 – 
Medical Devices – 




CMI SOP ENG-007 
“Risk Analysis 
Procedure” 
Risk Management Section of 
Technical Dossier Body TF-0018 
 
Risk Management File in Risk 
Management Attachment of 
Technical Dossier TF-0018 
 
Labeling and Instructions for Use 
Section of Technical Dossier 
CONTRACT MEDICAL INTERNATIONAL 
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Location of Documents: 
Comments: 
3. The devices must achieve the performances 
intended by the manufacturer and be designed, 
manufactured and packaged in such a way that 
they are suitable for one or more of the functions 
referred to in Article 1 (2) (a), as specified by the 
manufacturer. 
  Verification/Val
idations of MR 































ISO 11070: Sterile single-use 
intravascular catheter 
introducers 
Clinical Usage Requirements 
ASTM F2182 - 02a: Standard 
Test Method for Measurement 
of Radio Frequency Induced 
Heating Near Passive 
Implants During Magnetic 
Resonance Imaging 
ASTM F2119 - 07 Standard 
Test Method for Evaluation of 
MR Image Artifacts from 
Passive Implants 
ASTM F2213 - 06 Standard 
Test Method for Measurement 
of Magnetically Induced 
Torque on Medical Devices in 
the Magnetic Resonance 
Environment 
ISO 10993-1: 2003 
“Biological evaluation of 
medical devices-Part 1: 
Evaluation and testing” 
 
ISO 11607-1:2006 Packaging 
for terminally sterilized 




CMI-set test standards 
 
Summary of design verification / 
validation in main body of the 
Technical Dossier TF-0018 
 
Verifications/Validations/Testing 
Attachment of Technical Dossier 
TF-0018 
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Location of Documents: 
Comments: 
4. The characteristics and performances referred to in 
Sections 1, 2 and 3 must not be adversely affected 
to such a degree that the clinical conditions and 
safety of the patients and, where applicable, of 
other persons are compromised during the lifetime 
of the device as indicated by the manufacturer, 
when the device is subjected to the stresses which 
can occur during normal conditions of use. 
  Age Testing 
NOT required 




idations of MR 


























ISO 11070: Sterile single-use 
intravascular catheter 
introducers 
Clinical Usage Requirements 
ASTM F2182 - 02a: Standard 
Test Method for Measurement 
of Radio Frequency Induced 
Heating Near Passive 
Implants During Magnetic 
Resonance Imaging 
ASTM F2119 - 07 Standard 
Test Method for Evaluation of 
MR Image Artifacts from 
Passive Implants 
ASTM F2213 - 06 Standard 
Test Method for Measurement 
of Magnetically Induced 
Torque on Medical Devices in 
the Magnetic Resonance 
Environment 
ISO 10993-1: 2003 
“Biological evaluation of 
medical devices-Part 1: 
Evaluation and testing” 
 
ISO 11607-1:2006 Packaging 
for terminally sterilized 




CMI-set test standards 
 
Summary of design verification / 
validation in main body of the 
Technical Dossier TF-0018 
 
Verifications/Validations/Testing 
Attachment of Technical Dossier 
TF-0018 
 
CONTRACT MEDICAL INTERNATIONAL 
   ESSENTIAL REQUIREMENTS CHECKLIST 
 
REG-F002 REV. 0 ISSUED:  17.10.08 SOP REF:  REG-001  Page Number:  S2 - 112 of S2 - 178 
 









Location of Documents: 
Comments: 
5. The devices must be designed, manufactured and 
packed in such a way that their characteristics and 
performances during their intended use will not be 
adversely affected during transport and storage 
taking account of the instructions and information 
provided by the manufacturer. 
  RK-031 Risk 
Management 
File for MR 
Safe Guide 
Wire 
ISO 14971:2007 – 
Medical Devices – 




CMI SOP ENG-007 
“Risk Analysis 
Procedure” 
Risk Management Section of 
Technical Dossier Body TF-0018 
 
Risk Management File in Risk 
Management Attachment of 






ENG-017: CMI Pouch 
Sealing Validation 
SOP  
See Packaging Qualification 
Section of Main Body of 
Technical Dossier TF-0018. 
 
Packaging Attachment of 









for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
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CMI Inspection Specs. 
 




Manufacturing Flow Chart 
Attachment of Technical Dossier 
TF-0018 
 
Design Master Record 
Attachment of TF-0018, 
including inspection 
specifications 
6. Any undesirable side effect must constitute an 
acceptable risk when weighed against the 
performances intended. 
  RK-031 Risk 
Management 
File for MR 
Safe Guide 
Wire 
ISO 14971:2007 – 
Medical Devices – 




CMI SOP ENG-007 
“Risk Analysis 
Procedure” 
Risk Management Section of 
Technical Dossier Body TF-0018 
 
Risk Management File in Risk 
Management Attachment of 
Technical Dossier TF-0018 
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Location of Documents: 
Comments: 
II. REQUIREMENTS REGARDING DESIGN AND 
CONSTRUCTION 
     
7. Chemical, physical and biological properties      
7.1 The devices must be designed and 
manufactured in such a way as to guarantee 
the characteristics and performances referred 
to in Section I on the General requirements.  
Particular attention must be paid to: 
 the choice of materials used, particularly 
as regards toxicity and, where 
appropriate flammability, 
 the compatibility between the materials 
used and biological tissues, cells and 
body fluids, taking account of the 

















Biocompatibility Section of Main 




Attachment of Technical File TF-
0018 
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   ESSENTIAL REQUIREMENTS CHECKLIST 
 
REG-F002 REV. 0 ISSUED:  17.10.08 SOP REF:  REG-001  Page Number:  S2 - 115 of S2 - 178 
 









Location of Documents: 
Comments: 
7.2 The devices must be designed, manufactured 
and packed in such a way as to minimize the 
risk posed by contaminants and residues to 
the persons involved in transport, storage and 
use of the devices and to the patients, taking 
account of the intended purpose of the 
product.  Particular attention must be paid to 
the tissues exposed and to the duration and 
frequency of exposure. 















to EN 550: 
Sterilization of 
medical devices. 
Validation and routine 
control of ethylene 
oxide sterilization with 





by Ethylene Oxide. 
 









Refer to Sterilization Section in 
Main Body of Technical Dossier 
TF-0018 
 
Refer to Sterilization Attachment 
of TF-0018 
 
Refer to Bioburden Attachment 
of TF-0018 
 
Refer to Bioburden Statements in 
main technical file body TF-0018. 
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CMI Inspection Specs. 
 




Manufacturing Flow Chart 
Attachment of Technical Dossier 
TF-0018 
 
Design Master Record 








CMI SOP: RA-004 
“General QA 
Inspection Procedure” 
Refer to Device Master Record 
Attachment of Technical file TF-
0018. 
7.3 The devices must be designed and 
manufactured in such a way that they can be 
used safely with the materials, substances 
and gases with which they enter into contact 
during their normal use or during routine 
procedures;  if the devices are intended to 







Summary of design verification / 
validation in main body of the 
Technical Dossier TF-0018 
 
Verifications/Validations/Testing 
Attachment of Technical Dossier 
TF-0018 
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Location of Documents: 
Comments: 
designed and manufactured in such a way as 
to be compatible with the medicinal products 
concerned according to the provisions and 
restrictions governing these products and that 
their performance is maintained in 
accordance with the intended use. 
Device Design 
Specifications 
ISO 11070: Sterile single-use 
intravascular catheter 
introducers 
Design History File 
Device Master Record 
Refer to Design Specification 
Section in Main Technical File 
Body of TF-0018 
 
Refer to Device Master Record 
Attachment in TF-0018 
 
Refer to Verifications and 




File for MR 
Safe Guide 
Wire 
ISO 14971:2007 – 
Medical Devices – 




CMI SOP ENG-007 
“Risk Analysis 
Procedure” 
Risk Management Section of 
Technical Dossier Body TF-0018 
 
Risk Management File in Risk 
Management Attachment of 
Technical Dossier TF-0018 
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for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
7.4 There a device incorporates, as an integral 
part, a substance which, if used separately, 
may be considered to be a medicinal product 
as defined in Article I of Directive 
65/65/EEC and which is liable to act upon 
the body with action ancillary to that of the 
device, the safety, quality and usefulness of 
the substance must be verified, taking 
account of the intended purpose of the 
device, by analogy with the appropriate 
methods specified in Directive 75/318/EEC. 
  N/A N/A The device does not incorporate 
and is not considered a medicinal 
product. The device does not 
contain any materials that could 
be considered medicinal products. 
7.5 The devices must be designed and 
manufactured in such a way as to reduce to a 
minimum the risks posed by substances 
leaking from the device. 
  N/A N/A The device is a solid guide wire. 
There are no internal lumens or 
holes in the device. No fluid 
passes into or through the device. 
The device cannot leak. 
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Location of Documents: 
Comments: 
7.6 Devices must be designed and manufactured 
in such a way as to reduce, as much as 
possible, risks posed by the unintentional 
ingress of substances into the device taking 
into account the device and the nature of the 








Summary of design verification / 
validation in main body of the 
Technical Dossier TF-0018 
 
Verifications/Validations/Testing 




ISO 11070: Sterile single-use 
intravascular catheter 
introducers 
Design History File 
Device Master Record 
Refer to Design Specification 
Section in Main Technical File 
Body of TF-0018 
 
Refer to Device Master Record 
Attachment in TF-0018 
 
Refer to Verifications and 




File for MR 
Safe Guide 
Wire 
ISO 14971:2007 – 
Medical Devices – 




CMI SOP ENG-007 
“Risk Analysis 
Procedure” 
Risk Management Section of 
Technical Dossier Body TF-0018 
 
Risk Management File in Risk 
Management Attachment of 
Technical Dossier TF-0018 
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for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
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Location of Documents: 
Comments: 
8. Infection and microbial contamination      
8.1 The devices and manufacturing processes 
must be designed in such a way as to 
eliminate or reduce as far as possible the risk 
of infection to the patient, user and third 
parties.  The design must allow easy 
handling and, where necessary, minimize 
contamination of the device by the patient or 
vice versa during use. 















to EN 550: 
Sterilization of 
medical devices. 
Validation and routine 
control of ethylene 
oxide sterilization with 





by Ethylene Oxide. 
 









Refer to Sterilization Section in 
Main Body of Technical Dossier 
TF-0018 
 
Refer to Sterilization Attachment 
of TF-0018 
 
Refer to Bioburden Attachment 
of TF-0018 
 
Refer to Bioburden Statements in 
main technical file body TF-0018. 
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CMI Inspection Specs. 
 




Manufacturing Flow Chart 
Attachment of Technical Dossier 
TF-0018 
 
Design Master Record 






SOP of CMI: ENG-
019 “Bioburden 
Procedure” 
Sterilization Description in Main 
Technical File of TF-0018 
 
Routine Bioburden Results 
maintained on file at CMI  
Pyrogen testing 
 
SOP of CMI: ENG-
020 “LAL Testing 
Procedure” 
Sterilization Description in Main 
Technical File of TF-0018 
 
Routine LAL Test Results kept 
on File at CMI 
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for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
8.2  Tissues of animal origin must originate from 
animals that have been subjected to 
veterinary controls and surveillance adapted 
to the intended use of the tissues. 
Notified Bodies shall retain information on 
the geographical origin of the animals. 
Processing, preservation, testing and 
handling of tissues, cells and substances of 
animal origin must be carried out so as to 
provide optimal security.  In particular safety 
with regard to viruses and other transferable 
agents must be addressed by implementation 
of validated methods of elimination or viral 
inactivation in the course of the 
manufacturing process. 
  N/A N/A The device is a guide wire that 
does not contain animal tissue of 
any kind. The device is composed 
only of non-tissue materials. 
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Location of Documents: 
Comments: 
8.3 Devices delivered in a sterile state must be 
designed, manufactured and packed in a non-
reusable pack and/or according to 
appropriate procedures to ensure they are 
sterile when placed on the market and remain 
sterile, under the storage and transport 
conditions laid down, until the protective 
packaging is damaged or opened.  















to EN 550: 
Sterilization of 
medical devices. 
Validation and routine 
control of ethylene 
oxide sterilization with 





by Ethylene Oxide. 
 









Refer to Sterilization Section in 
Main Body of Technical Dossier 
TF-0018 
 
Refer to Sterilization Attachment 
of TF-0018 
 
Refer to Bioburden Attachment 
of TF-0018 
 
Refer to Bioburden Statements in 
main technical file body TF-0018. 
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ENG-017: CMI Pouch 
Sealing Validation 
SOP  
See Packaging Qualification 
Section of Main Body of 
Technical Dossier TF-0018. 
 
Packaging Attachment of 
Technical Dossier TF-0018. 
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Location of Documents: 
Comments: 
8.4 Devices delivered in a sterile state must have 
been manufactured and sterilized by an 
appropriate, validated method. 















to EN 550: 
Sterilization of 
medical devices. 
Validation and routine 
control of ethylene 
oxide sterilization with 





by Ethylene Oxide. 
 









Refer to Sterilization Section in 
Main Body of Technical Dossier 
TF-0018 
 
Refer to Sterilization Attachment 
of TF-0018 
 
Refer to Bioburden Attachment 
of TF-0018 
 
Refer to Bioburden Statements in 
main technical file body TF-0018. 
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Location of Documents: 
Comments: 
8.5 Devices intended to be sterilized must be 
manufactured in appropriately controlled 
(e.g. environmental) conditions. 
  Manufacturing 
Flow Chart 




CMI Inspection Specs. 
 




Manufacturing Flow Chart 
Attachment of Technical Dossier 
TF-0018 
 
Design Master Record 






an ISO 14698 






ISO Class 8.  
 
 





CMI SOP: ENG-009 
“GMP & Compliance 






Validation and Verification of 




CONTRACT MEDICAL INTERNATIONAL 
   ESSENTIAL REQUIREMENTS CHECKLIST 
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Location of Documents: 
Comments: 
8.6 Packaging systems for non-sterile devices 
must keep the product without deterioration 
at the level of cleanliness stipulated and, if 
the devices are to be sterilized prior to use, 
minimize the risk of microbial 
contamination; the packaging system must 
be suitable taking account of the method of 
sterilization indicated by the manufacturer. 
  N/A N/A Device is delivered sterile so 
packaging for non-sterile devices 
does not apply. 
8.7 The packaging and/or label of the device 
must distinguish between identical or similar 
products sold in both sterile and non-sterile 
condition. 
  N/A N/A Device is ONLY delivered sterile. 
Therefore no distinction between 
sterile and non-sterile products 
should be made. 
9. Construction and environmental properties      
9.1 If the device is intended for use in 
combination with other devices or 
equipment, the whole combination, including 
the connection system must be safe and must 
not impair the specified performances of the 
devices.  Any restrictions on use must be 
indicated on the label or in the instructions 
for use. 
  RK-031 Risk 
Management 
File for MR 
Safe Guide 
Wire 
ISO 14971:2007 – 
Medical Devices – 




CMI SOP ENG-007 
“Risk Analysis 
Procedure” 
Risk Management Section of 
Technical Dossier Body TF-0018 
 
Risk Management File in Risk 
Management Attachment of 
Technical Dossier TF-0018 
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Testing In Vivo 
 
 
Clinical Usage Requirements 
ASTM F2182 - 02a: Standard 
Test Method for Measurement 
of Radio Frequency Induced 
Heating Near Passive 
Implants During Magnetic 
Resonance Imaging 
ASTM F2119 - 07 Standard 
Test Method for Evaluation of 
MR Image Artifacts from 
Passive Implants 
ASTM F2213 - 06 Standard 
Test Method for Measurement 
of Magnetically Induced 
Torque on Medical Devices in 




Summary of design verification / 
validation in main body of the 
Technical Dossier TF-0018 
 
Verifications/Validations/Testing 
Attachment of Technical Dossier 
TF-0018 
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Location of Documents: 
Comments: 
9.2 Devices must be designed and manufactured 
in such a way as to remove or minimize as 
far as is possible: 
     
 the risk of injury, in connection with their 
physical features, including the 
volume/pressure ratio, dimensional and 
where appropriate ergonomic features, 
  RK-031 Risk 
Management 
File for MR 
Safe Guide 
Wire 
ISO 14971:2007 – 
Medical Devices – 




CMI SOP ENG-007 
“Risk Analysis 
Procedure” 
Risk Management Section of 
Technical Dossier Body TF-0018 
 
Risk Management File in Risk 
Management Attachment of 
Technical Dossier TF-0018 
 risks connected with reasonably foreseeable 
environmental conditions, such as magnetic 
fields, external electrical influences, 
electrostatic discharge, pressure, temperature 
or variations in pressure and acceleration, 
  RK-031 Risk 
Management 
File for MR 
Safe Guide 
Wire 
ISO 14971:2007 – 
Medical Devices – 




CMI SOP ENG-007 
“Risk Analysis 
Procedure” 
Risk Management Section of 
Technical Dossier Body TF-0018 
 
Risk Management File in Risk 
Management Attachment of 
Technical Dossier TF-0018 
 the risks of reciprocal interference with other 
devices normally used in the investigations 
or for the treatment given, 
  N/A N/A Device does not deliver or 
produce any signals that would 
produce a reciprocal interface. 
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Location of Documents: 
Comments: 
 risks arising where maintenance or 
calibration are not possible (as with 
implants), from aging of the materials used 
or loss of accuracy of any measuring or 
control mechanism. 
  N/A N/A Device does not contain any 
calibration because the device 
cannot measure in any way. 
9.3 Devices must be designed and manufactured 
in such a way as to minimize the risks of fire 
or explosion during normal use and in single 
fault condition.  Particular attention must be 
paid to devices whose intended use includes 
exposure to flammable substances or to 
substances which could cause combustion 
  N/A N/A Guide wire does not contain any 
flammable materials, and there 
are no influences that the device 
is exposed to during use that 
would cause the device to 
explode. 
10. Devices with a measuring function      
10. 1 Devices with a measuring function must be 
designed and manufactured in such a way as 
to provide sufficient accuracy and stability 
within appropriate limits of accuracy and 
taking account of the intended purpose of the 
device.  The limits of accuracy must be 
indicated by the manufacturer. 
  N/A N/A Guide wire does not contain a 
measuring function. 
10.2 The measurement, monitoring and display 
scale must be designed in line with 
ergonomic principles, taking account of the 
intended purpose of the device. 
  N/A N/A Guide wire does not contain a 
measuring function. 
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Location of Documents: 
Comments: 
10.3 The measurements made by devices with a 
measuring function must be expressed in 
legal units conforming to the provisions of 
Council Directive 80/181/EEC, as last 
amended by Directive 89/617/EEC. 
  N/A N/A Guide wire does not contain a 
measuring function. 
11. Protection against radiation   N/A N/A Device does not emit any 
radiation. 
11.1 General      
11.1.1 Devices shall be designed and 
manufactured such that exposure of 
patients, users and other persons to 
radiation shall be reduced as far as 
possible compatible with the 
intended purpose, whilst not 
restricting the application of 
appropriate specified levels for 
therapeutic and diagnostic 
purposes. 
  N/A N/A Device does not emit any 
radiation. 
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Location of Documents: 
Comments: 
11.2 Intended radiation      
11.2.1 Where devices are designed to emit 
hazardous levels of radiation 
necessary for a specific medical 
purpose the benefit of which is 
considered to outweigh the risks 
inherent in the emission, it must be 
possible for the user to control the 
emissions.  Such devices shall be 
designed and manufactured to 
ensure reproducibility and tolerance 
of relevant variable parameters. 
  N/A N/A Device does not emit any 
radiation. 
11.2.2 Where devices are intended to emit 
potentially hazardous, visible 
and/or radiation, they must be 
fitted, where practicable, with 
visual displays and/or audible 
warnings of such emissions. 
  N/A N/A Device does not emit any 
radiation. 
11.3 Unintended radiation      
11.3.1 Devices shall be designed and 
manufactured in such a way that 
exposure of patients, users and 
other persons to the emission of 
unintended, stray or scattered 
radiation is reduced as far as 
possible. 
  N/A N/A Device does not emit any 
radiation. 
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11.4 Instructions      
11.4.1 The operating instructions for 
devices emitting radiation must 
give detailed information as to the 
nature of the emitted radiation, 
means of protecting the patient and 
the user and on ways of avoiding 
misuse and of eliminating the risks 
inherent in installation. 
  N/A N/A Device does not emit any 
radiation. 
11.5 Ionizing radiation      
11.5.1 Devices intended to emit ionizing 
radiation must be designed and 
manufactured in such a way as to 
ensure that, where practicable, the 
quantity, geometry and quality of 
radiation emitted can be varied and 
controlled taking into account the 
intended use. 
  N/A N/A Device does not emit any 
radiation. 
11.5.2 Devices emitting ionizing radiation 
intended for diagnostic radiology 
shall be designed and manufactured 
in such a way as to achieve 
appropriate image and/or output 
quality for the intended medical 
purpose whilst minimizing 
radiation exposure of the patient 
and user. 
  N/A N/A Device does not emit any 
radiation. 
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11.5.3 Devices emitting ionizing radiation, 
intended for therapeutic radiology 
shall be designed and manufactured 
in such a way as to enable reliable 
monitoring and control of the 
delivered dose, the beam type and 
energy and where appropriate the 
quality of radiation. 
  N/A N/A Device does not emit any 
radiation. 
12. Requirements for medical devices connected to or 
equipped with an energy source 
  N/A N/A Device is not equipped with or 
connected to an energy source. 
12.1 Devices incorporating electronic 
programmable systems must be designed to 
ensure the repeatability, reliability and 
performance of these systems according to 
their intended use.  In the event of a single 
fault condition (in the system) appropriate 
means should be adopted to eliminate or 
reduce as far as possible consequent risks. 
  N/A N/A Device is not equipped with or 
connected to an energy source. 
12.2 Devices where the safety of the patients 
depends on an internal power supply must 
be equipped with a means of determining 
the state of the power supply. 
  N/A N/A Device is not equipped with or 
connected to an energy source. 
12.3 Devices where the safety of the patients 
depends on an external power supply must 
include an alarm system to signal any 
power failure. 
  N/A N/A Device is not equipped with or 
connected to an energy source. 
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12.4 Devices intended to monitor one or more 
clinical parameters of a patient must be 
equipped with appropriate alarm systems to 
alert the user of situations which could lead 
to death or severe deterioration of the 
patient's state of health. 
  N/A N/A Device is not equipped with or 
connected to an energy source. 
12.5 Devices must be designed and 
manufactured in such a way as to minimize 
the risks of creating electromagnetic fields 
which could impair the operation of other 
devices or equipment in the usual 
environment. 
  N/A N/A Device is not equipped with or 
connected to an energy source. 
12.6 Protection against electrical risks 
Devices must be designed and 
manufactured in such a way as to avoid, as 
far as possible, the risk of accidental 
electric shocks during normal use and in 
single fault condition, provided the devices 
are installed correctly. 
  
N/A N/A Device is not equipped with or 
connected to an energy source. 
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12. 7 Protection against mechanical and thermal 
risks 
     
12.7.1 Devices must be designed and 
manufactured in such a way as to 
protect the patient and user against 
mechanical risks connected with, 
for example, resistance, stability 
and moving parts. 
  N/A N/A Device does not contain any 
moving parts or mechanical 
structures. 
12.7.2  Devices must be designed and 
manufactured in such a way as to 
reduce to the lowest possible level 
the risks arising from vibration 
generation by the devices, taking 
account of technical progress and of 
the means available for limiting 
vibrations, particularly at source, 
unless the vibrations are part of the 
specified performance. 
  N/A N/A Device does not contain any 
moving parts or mechanical 
structures. 
12.7.3 Devices must be designed and 
manufactured in such a way as to 
reduce to the lowest possible level 
the risks arising from the noise 
emitted, taking account of technical 
progress and of the means available 
to reduce noise, particularly at 
source, unless the noise emitted is 
part of the specified performance. 
  N/A N/A Device does not contain any 
moving parts or mechanical 
structures. 
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12.7.4  Terminals and connectors to the 
electricity, gas or hydraulic and 
pneumatic energy supplies which 
the user has to handle must be 
designed and constructed in such a 
way as to minimize all possible 
risks. 
  N/A N/A Device does not contain an 
energy supply. 
12.7.5 Accessible parts of devices 
(excluding any parts or areas 
intended to supply heat or reach 
given temperatures) and their 
surroundings must not attain 
potentially dangerous temperatures 
under normal use. 
  ECO-00985-
005: ASTM 






ASTM F2182 - 02a: Standard 
Test Method for Measurement 
of Radio Frequency Induced 
Heating Near Passive 
Implants During Magnetic 
Resonance Imaging 
ASTM F2119 - 07 Standard 
Test Method for Evaluation of 
MR Image Artifacts from 
Passive Implants 
ASTM F2213 - 06 Standard 
Test Method for Measurement 
of Magnetically Induced 
Torque on Medical Devices in 
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12.8 Protection against the risks posed to the 
patient by energy supplies or substances. 
     
12.8.1  Devices for supplying the patient 
with energy or substances must be 
designed and constructed in such a 
way that the flow-rate can be set 
and maintained accurately enough 
to guarantee the safety of the 
patient and of the user. 
  N/A N/A Device cannot supply patient with 
energy or substances. 
12.8.2 Devices must be fitted with the 
means of preventing and/or 
indicating any inadequacies in the 
flow-rate which could pose a 
danger. 
  N/A N/A Device cannot supply patient with 
energy or substances. 
Devices must incorporate suitable 
means to prevent, as far as possible, 
the accidental release of dangerous 
levels of energy from an energy 
and/or substance source. 
  N/A N/A Device cannot supply patient with 
energy or substances. 
12.9 The function of the controls and indicators 
must be clearly specified on the devices. 
  N/A N/A Device does not contain any 
controls or indicators. No 
instructions are marked on the 
device. 
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Where a device bears instructions required 
for its operation or indicates operating or 
adjustment parameters by means of a visual 
system, such information must be 
understandable to the user and, as 
appropriate, the patient. 
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13. Information supplied by the manufacturer      
13.1 Each device must be accompanied by the 
information needed to use it safely and to 
identify the manufacturer, taking account of 
the training and knowledge of the potential 
users. 
This information comprises the details on the 
label and the data in the instructions for use. 
As far as practicable and appropriate, the 
information needed to use the device safely 
must be set out on the device itself and/or on 
the packaging for each unit or, where 
appropriate, on the sales packaging.  If 
individual packaging of each unit is not 
practicable, the information must be set out 
in the leaflet supplied with one or more 
devices. 
Instructions for use must be included in the 
packaging for every device.  By way of 
exception, no such instructions for use are 
needed for devices in Class I or Class IIa if 
they can be used safely without any such 
instructions. 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
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13.2 Where appropriate, this information should 
take the form of symbols.  Any symbol or 
identification colour used must conform to 
the harmonized standards.  In areas for which 
no standards exist, the symbols and colours 
must be described in the documentation 
supplied with the device. 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
13.3 The label must bear the following 
particulars: 
     
a) the name or trade name and address of 
the manufacturer.  For devices imported 
into the Community, in view of their 
distribution in the Community, the label, 
or the outer packaging, or the instructions 
for use, shall contain in addition the 
name and address of either the person 
responsible referred to in Article 14(2) or 
of the authorized representative of the 
manufacturer established within the 
Community or of the importer 
established within the Community, as 
appropriate; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
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b) the details strictly necessary for the user 
to identify the device and the contents of 
the packaging; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
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d) where appropriate, the batch code, 
preceded by the word LOT or the serial 
number; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
e)  where appropriate, an indication of the 
date by which the device should be used, 
in safety, expressed as the year and 
month; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
CONTRACT MEDICAL INTERNATIONAL 
   ESSENTIAL REQUIREMENTS CHECKLIST 
 
REG-F002 REV. 0 ISSUED:  17.10.08 SOP REF:  REG-001  Page Number:  S2 - 145 of S2 - 178 
 









Location of Documents: 
Comments: 
f) where appropriate, an indication that the 
device is for single use; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
g) if the device is custom-made, the words 
custom made device; 
  N/A N/A Device is not custom made. 
Device is produced with a 
standard specification. 
h) if the device is intended for clinical 
investigations, the words exclusively for 
clinical investigations; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
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i) any special storage and/or handling 
conditions; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
j) any special operating instructions;   N/A N/A There are no special operating 
instructions that would require 
placement on the label of the 
device. 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
l) year of manufacture for active devices 
other than those covered by e).  This 
indication may be included in the batch 
or  serial number; 
  N/A N/A Device is not an active device. 
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for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
13.4 If the intended purpose of the device is not 
obvious to the user, the manufacturer must 
clearly state it on the label and in the 
instructions for use. 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
13.5 Wherever reasonable and practicable, the 
devices and detachable components must be 
identified, where appropriate in terms of 
batches, to allow all appropriate action to 
detect any potential risk posed by the devices 
and detachable components. 
  N/A N/A Device does not contain any 
detachable components. Device is 
single guidewire. 
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13.6 Where appropriate, the instructions for use 
must contain the following particulars: 
     
a) the details referred to in 13.3, with the 
exception of   d) and e); 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
b) the performances referred to in Section 3 
and any undesirable side-effects; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
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c) if the device must be installed with or 
connected to other medical devices or 
equipment in order to operate as required 
for its intended purpose, sufficient details 
of its characteristics to identify the 
correct devices or equipment to use in 
order to obtain a safe combination; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
d) all the information needed to verify 
whether the device is properly installed 
and can operate correctly and safely, plus 
details of the nature and frequency of the 
maintenance and calibration needed to 
ensure that the devices operate properly 
and safely at all times; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
e) where appropriate, information to avoid 
certain risks in connection with 
implantation of the device; 
  N/A N/A Device is not implantable. 
f) information regarding the risks of 
reciprocal interference posed by the 
presence of the device during specific 
investigations or treatment; 
  N/A N/A Device does not emit any signal 
that would create a reciprocal 
interface. 
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g) the necessary instructions in the event of 
damage to the sterile packaging and, 
where appropriate, details of appropriate 
methods of re-sterilization; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
h) if the device is reusable, information on 
the appropriate processes to allow reuse, 
including cleaning, disinfection, 
packaging and, where appropriate, the 
method of sterilization of the device to be 
resterilized, and any restriction on the 
number of reuses. 
Where devices are supplied with the 
intention that they can be sterilized 
before use, the instructions for cleaning 
and sterilization must be such that, if 
correctly followed, the device will still 
comply with the requirements in Section 
l; 
  N/A N/A Device is Single Use Only. 
i) details of any further treatment or 
handling needed before the device can be 
used (for example, sterilization, final 
assembly, etc.); 
  N/A N/A Device does not require any 
assembly or special handling 
before use. 
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j) in the case of devices omitting radiation 
for medical purposes, details of the 
nature, type, intensity and distribution of 
this radiation. 
  N/A N/A Device does not emit any 
radiation. 
The instructions for use must also include 
details allowing the medical staff to brief 
the patient on any contra-indications and 
any precautions to be taken.  These 
details should cover in particular: 
     
k) precautions to be taken in the event of 
changes in the performance of the device; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
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l) precautions to be taken as regards 
exposure, in reasonably foreseeable 
environmental conditions, to magnetic 
fields, external electrical influences, 
electrostatic discharge, pressure or 
variations in pressure, acceleration, 
thermal ignition sources, etc.; 







for use in the labeling 




by the manufacturer 
with medical devices” 
 
Labels located in Labels and 
Instructions For Use Attachment 
of Technical File TF-0018 
 
m) adequate information regarding the 
medicinal product or products which the 
device in question is designed to 
administer, including any limitations in 
the choice of substances to be delivered; 
  N/A N/A Device is not capable or intended 
to deliver medicinal products. 
n) precautions to be taken against any 
special, unusual risks related to the 
disposal of the device; 
  N/A N/A Device does not require any 
special disposal. 
o) medicinal substances incorporated into 
the devices as an integral part in 
accordance with Section 7.4; 
  N/A N/A Device is not capable or intended 
to deliver medicinal products. 
p) degree of accuracy claimed for devices 
with a measuring function. 
  N/A N/A Device does not contain a 
measuring function. 
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14. Where conformity with the essential requirements 
must be based on clinical data, as in Section 1 (6), 
such data must be established in accordance with 
Annex X. 
  N/A N/A Device is being used for clinical 
testing. Data will be established 
according to Annex X, however 
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Risk management / Market observation   /    Risk analysis 
 
In vitro Physical/Mechanical Testing: 
 
Test and Description Standard for Test Results   Acceptance Criteria 
Test for Fracture of Guide Wires ISO 11070: Sterile Single Use intravascular catheter 
introducers: Annex F 
Passed with no signs of deformation. No cracking or 
breakage of wire 
No signs of fracture and 
no flaking of the coating 
Flexibility Test ISO 11070: Sterile Single Use intravascular catheter 
introducers: Annex G 
Guide wire displayed flexible behavior and had no 
defects after being subjected to the flexibility test 
No signs of defects or 
damage and no flaking 
of the coating 
Sliding Properties N/A Device was found to have low friction when being slid 
in a phantom set up. 
N/A 
Strength Test ISO 11070: Sterile Single Use intravascular catheter 
introducers: Annex H 
Passed 
 
Breaking Force of More 
than 10 Newtons 
ASTM testing of MR Guide 
Wire: RF-safety, MR image 
artifacts and magnetic interaction 
ASTM F2182 - 02a: Standard Test Method for 
Measurement of Radio Frequency Induced Heating 
Near Passive Implants During Magnetic Resonance 
Imaging 
ASTM F2119 - 07 Standard Test Method for 
Evaluation of MR Image Artifacts from Passive 
Implants 
ASTM F2213 - 06 Standard Test Method for 
Measurement of Magnetically Induced Torque on 
Medical Devices in the Magnetic Resonance 
Environment 
 
No significant heating beyond global SAR related 
tissue heating was found. Maximum temperature 
increase observed was 0.3°C at maximum scanner 
power (4W/kg). 
There were no set 
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number (A x 
B x E) 
Safety measure/Comment A B E RPZ R 
1 Toxicologic hazards  
(Materials and 
substances) 
             
1.1 complete guidewire Release of  toxic  
agents 
Materials or 





2 7 2 28 Proper material selection (cf. 
Documentation of materials); 
incoming goods inspection, 
Enclosure of hazardous materials 
1 7 1 7 yes 
               
2 Hazards due to energy 
and contributing 
factors 
             





Prolongation of  
Intervention 
2 6 2 24 Validated 
production/manufacturing 
processes; in-process-control; 
final inspection, instructions for 
use, safety by appropriate 
construction 
1 6 1 6 yes 





2 6 2 24 Safety by protective tubing  1  6 1 6 yes 
2.3 vessel perforation vascular injury and 
bleeding 
Stiffness of tip section 
too high 
surgical repair     Reduction of the stiffness of  the 
tip section, atraumatic rounded 
tip shape 
     
               
3 Biological hazards and 
contributing factors 
             





infection 2 5 2 20 Production under controlled 
conditions 
1 5 1 5 yes 
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3.2 complete guidewire Non-sterility Inappropriate 
sterilization process 
Sterilisationsprozess 
infection 2 5 2 20 Usage of validated sterilization 
cycle 
1 5 1 5 yes 
3.3 complete guidewire non-sterility leak in sterile 
packaging; 
inappropriate sealing of 
packaging 
infection 2 5 2 20 Validated packaging process; 
internal process control of 
production process;Note in label 
and instructions for use 
1 5 1 5 yes 
3.4 sterile packaging non-sterilty damaged sterile 
packagingg 
infection 2  5 2 20 Appropriate packaging material; 
Note in label and instructions for 
use 
1 5 1  5 yes 




             
 no known hazards              
5 Hazards due to 
delivery of energy or 
substances 
             
5.1 not relevant              
               
6 Hazards related to  the 
usage of the product 
             
6.1 guidewire vessel perforation misuse surgical repair 2 7 2 32 instructions for use 1 7 1 7 yes 
               
7 Inappropriate, 





             
7.1 guidewire sticking of the 
guidewire 







2 5 2 20 Information on appropriate guide 
catheter type & size, remark in 
instructions for use 
1 5 1 5 yes 
               





             
8.1 guidewire non-sterility   storage beyond 
expiration date of sterile 
packaging 
infection 1 5 2 10 Indication of expiration date in 
label 
1 5 1 5 yes 




expiration date of sterile 
packaging 
Surgical repair 2 7 2 28 Indication of expiration date in 
label 
1 5 1 5 yes 
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Risk management / Market observation   /    Risk analysis 
               
A = probabolity of occurence (1-10) low-high/B = Severity (1-10)low-high/E =Probability of detection (1-10) low-high/RZP = Risk priority number (A*B*E)/ R = Risk acceptance (Yes/No) 
 
Risk assessment 
Further risk mitigation not required.     
 
Risk management (applicable in case of required further risk mitigation, safety measures described in supplementary document) 
1. Risk mitigation 
2. Analysis of options (Determination of measures) 
3. Implementation of measures 
4. Assessment of residual risk 
5. Risk/benefit analysis 
6. Consideration of further hazards 
 
 
Overall residual risk assessment 
The overall residual risk is acceptable, because the benefit exceeds the residual risks. 
 
Risk management report 
Cf. document  „Risk management report“ as part of the technical documentation. 
 
 
The risk analysis was performed by: 
Title / Surname / Name Function / Qualification Signature 
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Company Name : Contract Medical International GmbH 
 
Model Name   : MR Safe Guidewire 
 
Model Number  : MG-35180-001 
 




1. Is the device made for:- 
            Single use 











If yes continue with 
question 3 if not go to 
question 8. 




      Sub-contractor   
Sub-
Contractor 
Please provide details of 
sterilization facility 




Lichtenberg GmbH (MPL) 
Gewerbegebiet Süd 18 
09618 Brand-Erbisdorf  
Germany 
Phone: 03732252590 
Ethylene Oxide Cycle 1.1 
4. By what method is the device sterilized 
 















and justification for 









NOTE: Attachment 1 
contains the Summary 
of the Validation as 
well as the internal 
report. The complete 








                       Chemical 
                       Biological 
      Dosimetric release 




















are routine sterility 
criteria. The results 
are evaluated by CMI 
and MPL with release 





0004 and Sterilization 
Verification ECO-
0933. 
6. Have bioburden determinations been 
undertaken 
Part will be 
routinely 
bioburden 
tested on a 
per lot basis. 
Please provide 




Device is tested to ISO 
11737-1 Sterilization 
of Medical devices- 
Microbiological 
Methods. 
Using the membrane 
filtration Method and 
examined for bacteria, 
spores, and funghi. 
 
Every lot of product 
will be tested. 
 
Results are not yet 
available for clinical 
trial lot; however, 
bioburden will be 
reviewed internally 
before the product is 
  
released and the 




7. Are environmental precautions 
undertaken on the device during: 
 
Manufacturing 







information e.g. type 
of controls, frequency 
of monitoring, results 




manufactured in an 




environment is ISO 
Class 8.  
 
Types of Controls: 
Microbiological 
Monitoring: 1 x  per 
month 
Particle Monitoring: 1 




1 x per day 
 
Results and Outcome: 
Results are trended on 
a time basis. Results 
are evaluated via alert 
and action levels. All 






is packaged in a 
sealed pouch before 
leaving the controlled 
environment. 











If device is not required 
to be sterilized do not 
  
a. Be sterilized at point of use 
 
b. Device is not required to be 
sterilized 
N/A continue 
9. If the device is to be sterilized at point 
of use: 
By what method:- 
 
      Steam 
 
      Chemical 
 









and justification for 
choice of sterilization 
process  
 
10. Are reprocessing instructions 
available:- 
 
      Instructions for 
decontamination/cleaning 
 
      Instructions for sterilization  
 






The device is 
not cleaned 
before use. 
The device is 
delivered 
sterile.  




Please provide copies 
of those instructions 








                       
                       Chemical 
                       Biological 
      Dosimetric release 






results and outcome  





information e.g. type 
(nature), frequency, 
results, outcome 
13. Are environmental precautions 
undertaken on the device during: 
 
      Manufacturing 








information e.g. type 
of controls, frequency 
of monitoring, results 
and outcome 
14. Has a ‘standard’ been applied to the 
any of the above processes: 
               International – ISO 
                European – EN 





Please provide the 
appropriate number 






to EN 550: 
Sterilization of 
medical devices. 
Validation and routine 
control of ethylene 
oxide sterilization 
with reference to: ISO 
11135: Sterilization of 
Healthcare Products 




























Dear Prof Razavi  
        CLINICAL INVESTIGATION: NO OBJECTION  
Manufacturer    : Contract Medical International GmbH  
Model Name      : MR GuideWire  
Model Number    : MG-35180-001  
Description     : MR Guide Wire  
Your notification dated : 18/09/2009  
Protocol version number : 1  
Number of patients      : 20  
Follow-up                            : as per routine follow-up  
I hereby notify you that the UK Competent Authority has no grounds for objection to the making available of the above medical device for the purposes of a clinical investigation as declared in the 
above notification. 
The device(s) must be labeled “exclusively for clinical investigations”.  
The Competent Authority's review of your notification led to some observations which are included at the end of this letter for your consideration. No response is necessary to these observations. 
The ethics committee opinion that forms part of the information required under Section 2.2 of Annex VIII must be provided to MHRA as soon as it becomes available. The clinical investigation must 
not commence at any UK centre until the relevant ethics committee approval is obtained. 
MHRA also requires confirmation that each individual site in this clinical investigation has received the necessary approvals. For NHS sites this approval must be obtained from the NHS/HSC R&D 
office and for non-NHS sites this approval must be obtained from your ethics committee. Please notify MHRA of the outcome of the relevant approvals for each site in this clinical investigation once 
received. Please note that this clinical investigation must not commence in any UK site until you have received the relevant approvals for that individual site and you have notified MHRA of this. 
Full details can be obtained from the National Research Ethics Service (NRES) (www.nres.npsa.nhs.uk) or by emailing queries@nationalres.org.uk. When contacting NRES you should make it clear 
that the investigation involves a non-CE marked medical device.  
The assessors who assisted with the evaluation of your notification will be sent a copy of this decision, for information only and strictly "in confidence". Our decision will also be notified to the 
relevant ethics committee(s) if you have confirmed that you are happy for us to do this. If you have not then you may wish to advise them of this decision yourself. 
We will retain all the documentation provided by you for one month from the date of this letter. After this time the documentation (except for one copy, retained for record purposes only) will be 
destroyed, unless you request its return. 
Adverse Incident Reporting  
You are reminded that Regulation 16(10)(a) of the Medical Devices Regulations 2002 (SI 618) and Annex X of the Medical Devices Directive 93/42 require you to record fully all adverse incidents 
and report all serious adverse incidents occurring in the UK to the Competent Authority. 
Such reports should be made to the MHRA (devices) Adverse Incident Centre and should include all serious adverse incidents, whether initially considered to be device related or not, that have 
occurred within the UK.  
A “serious adverse incident” is one which:  
 led to a death  
 led to a serious deterioration in the health of the patient, user or others and includes:  
 a life threatening illness or injury  
 a permanent impairment to a body structure or function  
 a condition requiring hospitalisation or increased length of existing hospitalisation  
 a condition requiring otherwise unnecessary medical or surgical intervention and which might have led to death or serious deterioration in 
health had suitable action or intervention not taken place. This includes a malfunction of the device such that it has to be monitored more 
closely or temporarily or permanently taken out of service  
 led to foetal distress, foetal death or a congenital abnormality or birth defect  
 might have led to any of the above  
Such adverse incidents that have occurred in the UK should be reported as soon as possible and in any case within 10 days of occurrence. When reporting these incidents please include the total 
number of patients treated in the UK at the time of reporting. 
Those incidents arising out of the same investigation being carried out at other participating centres, whether European or non-European, should be reported on a three monthly basis in a summary 
format, since such events may have direct influence on the status of the UK investigation. When providing these summaries please include: 
1. The number of serious adverse incidents from all participating centers in a simple tabular format laying out the percentages of each type of serious incident globally and 
from the UK with an indication as to how many of those are thought to be device related or non-device related.  
2.      The total number of patients recruited in the UK during that same 3 month period and in total;  
3.      The total number of patients recruited outside of the UK during that same 3 month period and in total;  
In the case of a blinded control clinical investigation using a CE marked device as control, all adverse events should be reported to MHRA in line with the requirements above.   
Where an un-blinded controlled clinical investigation is being carried out using a CE marked device as the control, adverse incidents involving the CE marked devices should be reported to the 
competent authority in line with vigilance guidelines.  
  
All adverse incident reports and manufacturer summary reports should be submitted to the Devices Adverse Incident Centre. We encourage you to use MHRA's manufacturers on-line reporting system 
(MORE) to submit this information. Details of this simple to use system and how to register for it can be found on the Device Adverse Incident reporting portions of the MHRA website 
(www.mhra.gov.uk), along with details of other methods of reporting. If using MORE, please include MHRA’s CI reference number in the ‘incident description’ field. 
Please note that adverse events involving a medicinal product should also be reported to MHRA Medicines by the manufacturer of the medicine or sponsor of the study. Information on the 
requirements for reporting of such events can be found on the MHRA website by clicking on the Yellow Card icon on the right hand side of the home page and then selecting ‘Information for the 
Pharmaceutical Industry’ from the left hand menu. 
Amendments  
You must notify the Competent Authority of all proposed changes to this investigation and await our letter of no objection before you implement them. This includes changes relating to the device, 
clinical investigation plan, investigators or investigating institutions, and changes made upon the request of an ethics committee. Failure to notify us of proposed changes could result in the 
manufacturer being liable to prosecution. 
When notifying changes, please provide the following information:  
 the reference number shown at the top of this letter.  
 the proposed change(s) to the clinical investigation plan/design of device/other study documentation.  
 the reason for the change(s).  
 a signed statement by or on behalf of the manufacturer that the proposed change(s) do not predictably increase the risk to the patient, user or third party.  
Final Report  
Under Regulation 16(10) of the Medical Devices Regulations 2002 (SI 618) the written report of a completed clinical investigation must be kept available for the Secretary of State if required. MHRA 
may request a copy of the written report for scrutiny. 
A letter informing the Competent Authority of when the trial has been completed would be appreciated.  
CE Marking  
MHRA would be interested to know when the device under investigation is CE marked and would be most grateful for notification of this once completed. 
Competent Authority Comments  
Please ensure that you note and understand the requirements set out above for reporting adverse incidents to the UK Competent Authority. 
 
Yours sincerely  
 
Mr Rob Higgins  
(on behalf of the Competent Authority, UK)  
Tel: 020 7084 3185  
Fax: 020 7084 3107  
Email: Rob.Higgins@mhra.gsi.gov.uk  
 
  
  
  
  
 
 
 
 
 
  
 
 
 
 
 
  
 
  
 
 
 
